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Abstract 
Pregnancy; a natural insulin resistant state; becomes exaggerated when complicated 
by obesity and gestational diabetes (GDM). Both obesity and GDM are associated 
with severe maternal and fetal complications as well as with increased risks of 
obesity in the offspring later in life.  Little work has been performed on the levels of 
adipokines in lean, obese and diabetic pregnancy.  This study aimed to explore the 
roles of three adipokines; namely, Adipsin, Acylation stimulating protein and 
Fibroblast Growth Factor-21, all of which are involved in insulin resistant and 
dysmetabolic states such as obesity and type 2 DM.  We hypothesized that these 
adipokines might play a role in pregnancy. A cohort of Caucasian pregnant women 
undergoing elective caesarean section was studied.  Clinical parameters were assayed 
as well as circulating maternal and fetal levels of adipsin, ASP and FGF21. Paired 
samples of fat and placental tissue were taken for explant studies to measure secreted 
Adipsin, ASP and FGF21 levels.  Cord levels of adipsin and ASP were significantly 
elevated in the offspring of obese and diabetic mothers compared to their lean 
controls.  Plasma FGF21 levels were significantly higher in GDM compared to lean 
controls. FGF21 levels in cerebrospinal fluid (CSF) were also measured and a 
CSF/Plasma ratio calculated.  
I have identified the human placenta as a source of adipsin, ASP and FGF21. More 
specifically, I have shown that placental Hofbauer cells (macrophages) produce 
adipsin and ASP. This is the first time secretion of adipsin and ASP by Hofbauer 
cells has been demonstrated. I conjecture a role of these macrophages in lipid 
metabolism at the materno-fetal interface. Also, I describe that GDM mothers have 
higher CSF FGF21 as compared to controls but the CSF:plasma ratio of FGF21 was 
lower in GDM mothers, potentially suggesting an alternative reason for and 
contributing to hyperglycaemia in GDM. 
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Commonly used abbreviations and those not defined when they first appear within 
the text are listed below. 
 
Complement components: 
Nomenclature for human complement components is based on,  
Human Complement components are previously reported in Complement 
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CSF  Cerebrospinal fluid 
C3adesArg  Complement 3a desarginase 
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MCP-1  Monocyte Chemotactic Protein 
MDD Minimum detectable dose 
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NHLBI  The National Heart, Lung and Blood Institute 
OGTT  Oral Glucose Tolerance Test 
PAI-1   Plasminogen Activator Inhibitor-1 
PBS  Phosphate Buffered Saline 
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1.1. Introduction 
 
Obese pregnancy is evolving as a major risk for both mother and child.  Obesity has 
been noted as a significant risk factor for maternal death as more than fifty percent of 
all women who died reported as being obese according to the Confidential Enquiry 
into Maternal and Child Health., 2009 (Confidential Enquiry into Maternal and Child 
Health., 2009).   
The adverse outcomes from maternal obesity and maternal diabetes impact both the 
early and long-term fetal health and have been documented by numerous studies.  A 
principal complication on offspring from obese pregnancy and maternal diabetes is 
fetal macrosomia.  Many reports have showed that intrauterine exposure either to 
hyperglycemia or excessive nutrients might increase the risk and thus tend the 
offspring to develop obesity and/or else diabetes at the later life. Gestational diabetes 
and maternal obesity are the two main factors have been associated with insulin 
resistance as well as inflammation which are regulated by several adipokines and 
cytokines (Ategbo et al., 2006).  In general, obesity is linked with hyperlipidemia and 
increased adiposity (Dandona et al., 2004).  Low grade inflammation has been 
reported to have an association with insulin resistance, obesity and type 2 diabetes 
mellitus (Dandona et al., 2004).  Accordingly, it suggests that inflammation may 
possibly adapt insulin resistance in gestational diabetes. 
 
1.2 Definition of Obesity 
 
Obesity is a state of imbalance between calories ingested versus calories expended 
which can lead to excessive or abnormal fat accumulation (Morton, 2005).  The most 
universally used technique of body fat is Body mass index (BMI) which is defined as 
weight in kilograms (Kgs), divided by the square of height in meters (m
2
). 
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1.3 Classification of Obesity 
 
Obesity is generally classified based on Body Mass Index. BMI between 25 and 30 
kg/m
2 
is overweight; BMI greater than or equal to 30 kg/m
2 
is obesity and BMI 
greater or equal to 40 kg/m
2 
is extreme obesity.  World Health Organization (WHO) 
and The National Heart, Lung and Blood Institute (NHLBI), Classified the body 
mass index (World Health Organization. Division of Noncommunicable Diseases. 
and World Health Organization. Programme of Nutrition Family and Reproductive 
Health., 1998), as  
Underweight   <18.5 
 Normal    18.5–24.9 
 Overweight    25.0–29.9 
 Obesity class I  30.0–34.9 
 Obesity class II  35.0–39.9 
 Obesity class III  40+ 
 
1.4 Prevalence 
In the last 20 years, obesity rates have increased dramatically all over the world.  The 
World Health Organization in 2005, reported that as a minimum of 400 million 
adults were  found to be obese of  BMI  >30 with a predictable rise to above 700 
million by 2015 (World Health Organization. Office of Health Communications and 
Public Relations., 2006).   In developed countries, obesity has become a major public 
health issue and recently, over 1.1 billion of the population in the world were 
classified as obese (World Health Organization. Office of Health Communications 
and Public Relations., 2006, World Health Organization., 2009).  In UK, it has been 
reported that nearly 24% of all women are obese and 34% are overweight 
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(Confidential Enquiry into Maternal and Child Health., 2009).  In UK, there are 
about 50 % are found to be overweight or obese in women of reproductive age group 
and for about 15 years from 1990 to 2004, there has been an increase of 60% of  
obesity in pregnancy  (Heslehurst et al., 2007).  In Ireland, about one in five pregnant 
women who registered in antenatal clinics is found to be obese (Fattah et al., 2009).  
Around one-third of women of reproductive age were  classified as obese in the USA 
(World Health Organization., 2009) and similarly in the UK,  32% of women aged 
between 35and 64 years were found to be overweight (BMI 25–30) and 21% were 
obese
 
(Prescott-Clarke et al., 1998). In the developing world,  obesity is dramatically 
increasing particularly in urban (World Health Organization. Office of Health 
Communications and Public Relations., 2006). 
There are inadequate statistics in pregnant women regarding the incidence of obesity.  
The cohort studies in the UK have reported that there are increased levels of obesity 
comparable to the population as a whole (Kanagalingam et al., 2005, Usha Kiran et 
al., 2005, Heslehurst et al., 2007, Kim et al., 2007).
   
The underlying aetiology of 
obesity is multi factorial with more calories consumed than exhausted which results 
in energy imbalance.  Obesity is linked with an extensive range of medical 
complications like diabetes (Vazquez et al., 2007),  cardiovascular disease (Romero-
Corral et al., 2006),  dyslipidaemia and hypertension (Brown et al., 2000), cancer 
(Wolk et al., 2001)  and osteoarthritis (Lievense et al., 2002).  In UK and other 
Mediterranean countries, the prevalence of overweight among children age between 
5-11 years has increased significantly from steady level to nearly 30% (1980-2000) 
(Lobstein and Frelut, 2003, Stamatakis et al., 2005, Wang and Lobstein, 2006). 
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1.5 Pro-inflammatory state of Obesity   
Obesity  are linked with the tissue expansion of adipose tissue due to the lipids 
accumulation into adipocytes (Weyer et al., 2002, Sartipy and Loskutoff, 2003, 
Samad et al., 1996, Samad and Loskutoff, 1996, De Pergola and Pannacciulli, 2002).  
These expanded adipose tissues produce cytokines such as IL-6, resistin, TNF-α, 
PAI-1 and MCP-1, which are considered to be proinflammatory (Weisberg et al., 
2003, Xu et al., 2003).   These cytokines has effects on the endothelium locally 
which leads to the synthesis of intracellular  and vascular cell adhesion molecule 
which in turn increases vascular permeability of  monocytes, and chemokines like 
MCP-1 (Cinti et al., 2005).  A state of local and systemic insulin resistance is 
induced by the production of proinflammatory cytokines by the inflammatory signal 
which is improved by crosstalk among endothelial cells, resident macrophages and 
adipocytes (Bruun et al., 2003).  The inflammatory signal in adipose tissue is intiated 
by the lipids accumulation in adipocytes as well as by resident macrophages. 
 
1.6 Obesity and insulin resistance 
Obesity is defined as a chronic low grade inflammation which has an important 
relationship between obesity and insulin resistance.  For many years, adipocyte and 
metabolic disturbances has been linked between insulin resistance and obesity.  
Initially, adipose tissue was considered as a storage organ of excessive triglycerides.  
But  recently,  this view has altered and adipose tissue has revealed to produce a wide 
variety of cytokines which influences both metabolic and physiological functions 
(Halberg et al., 2008).  Due to excessive triglycerides storage in obesity which leads 
to adipogenesis in turn results in hypertrophy as well as hyperplasia of adipocytes  
(Avram et al., 2007), which in turn results in cellular dysfunction leading to 
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adipokines dysregulation, increased FFA release and inflammation.  The excessive 
FFA leads to fat accumulation in different areas like liver, heart, pancreatic cells and 
skeletal muscle (de Ferranti and Mozaffarian, 2008).  Excessive ectopic fat 
deposition in skeletal muscle increases peripheral insulin resistance by reduced 
insulin mediated glucose uptake (Boden, 2006).  The elevated FFA in liver leads to 
reduced extraction of insulin, which leads to systemic hyperinsulinaemia and altered 
gluconeogenesis (Boden, 2006).  The excessive FFA in pancreatic cells contributes 
still further to the relative insulin deficiency state (Lupi et al., 2002).   Obesity in 
pregnancy has definite effects on glucose metabolism with a decrease in fasting 
glucose in early gestation and with considerable increase in hepatic insulin resistance 
and in peripheral tissues (Mills et al., 1998, Sivan et al., 1997).  Moreover, women 
with obesity are liable to risk of 4 times to have gestational diabetes and morbidly 
obese  about  9 times than lean women (Chu et al., 2007a).  These increased risks are 
due to multifactorial mechanisms, and has effects on insulin signaling similar to  
non-pregnant women with high BMI (Catalano et al., 2002). 
 
1.7 Effects on adipocytes in obesity 
The adipocytes enlarge in obesity, with adipose tissue consecutively undergoing 
cellular and molecular alterations that result in altered systemic metabolism.  The 
fasting free fatty acid and release of glycerol  from adipocytes is found to be higher 
in obese women compared with women with normal BMI which induces insulin 
resistance (Horowitz and Klein, 2000).  Increased release of free fatty acids are 
shown to induce insulin resistance in muscle (Shulman, 2000) and this is due to 
alterations in the expression of key phosphoproteins, perilipins.  Perilipins are found 
in adipocytes on the surface of triacylglycerol droplets which acts as gatekeepers and 
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prevents the lipases from hydrolyzing triacylglycerol to allow FFAs release (Zhang 
et al., 2003).  Even though the fat cells are larger in obesity, they were to found to be 
perilipins deficient and their basal rate of lipolysis are increased (Wang et al., 2003). 
The numbers of macrophages in adipose tissue also increase with obesity (Weisberg 
et al., 2003).  Macrophages are found to be responsible for the production of most 
cytokines in adipose tissues of obese individuals (Weisberg et al., 2003, Xu et al., 
2003) and  with increase in obesity these  macrophages are found to scavenge 
moribund adipocytes (Cinti et al., 2005). 
 
1.8 Pregnancy 
Pregnancy is a natural inflammatory state with leucocytes activation and increased 
concentration of cytokines and acute phase reactants, systemically (Klover et al., 
2003).  When it is complicated by preeclampsia and gestational diabetes, there is an 
exaggeration of physiological inflammatory state, returning to baseline levels after 
delivery (Pradhan et al., 2001, Ridker et al., 2000, Wake and Walker, 2004).  This 
exaggerated physiological inflammatory state results in an increased release of the 
inflammatory products by the placenta and thus these micro particles are released 
into the systemic circulation which are detaching from the syncytial surface of the 
placenta (Dandona et al., 2004, Kern et al., 2001, Dandona et al., 1998).  The 
inflammatory changes in pregnancy are mediated mainly in the placenta which 
regulates both adaptive and innate immune responses. 
The macrophages which are produced from hematopoietic cells in fetus are identified 
in the placenta in the very early stage of development (Vozarova et al., 2001, 
Wakabayashi, 1998) which exhibit cytokines and immunoregulatory molecular 
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profile to macrophages in adipose tissue;  however, their precise role in the placenta 
is not well understood.  
 
1.9 Pregnancy and insulin resistance 
Pregnancy is normally linked with distinct changes in metabolism of glucose and 
insulin resistance (IR) to aid stipulation of fuel substrate for the growing fetus.  There 
is an increase in the secretion of insulin in early pregnancy, whilst insulin sensitivity 
is stable or even more slightly enhanced (Catalano et al., 1993, Catalano et al., 1999).  
The insulin mediated utilisation of glucose decreases by 40-60% and increases in 
insulin secretion as pregnancy progresses to facilitate euglycaemic state in mother 
(Catalano et al., 1991, Catalano et al., 1992).  The primary glucose disposal site is 
considered to be the skeletal muscle, but in the latter half of gestation, there is 
severely insulin resistant in the adipose tissue.  During late gestation, the insulin  
decreases lipolysis, which leads to larger postprandial increases in free fatty acids, 
amplified gluconeogenesis and insulin resistance (IR) (Homko et al., 1999).  
Pregnancy is physiologically associated with insulin resistance and 
hyperinsulinaemia, which predispose vulnerable women to develop diabetes in 
pregnancy.  This insulin resistance is predominantly prominent in the second half of 
gestation, with increased insulin resistance subsequently contributing to the 
development of gestational diabetes (GDM).  
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1.10 Role of lipids in pregnancy 
Adaptations  of  maternal  lipid  metabolism  throughout the pregnancy plays a major 
role in the growth of  fetus.  The altered maternal lipid metabolism which occurs 
normally during the gestational period are the  lipids accumulation in maternal 
tissues (Hytten and Robertson, 1971, Villar et al., 1992) and the development of 
maternal hyperlipidemia (Alvarez et al., 1996, Montelongo et al., 1992).  The 
common conditions which are known to alter these two manifestations by impairing 
maternal fat deposition such as diabetes or hypothyrodism during first trimester have 
been shown to affect growth of fetus at late trimester even with the treatment during 
the second trimester (Bonet and Herrera, 1991, Martin and Herrera, 1991).  The 
development of fetus are maintained by metabolites crossing the placenta from those 
nutrients present in maternal circulation.  The most important nutrient which crosses 
the placenta is glucose, subsequently amino acids and fetal developmental directly 
depends on their availability (Herrera et al., 1985, Hay, 1994, Sibley et al., 1997).  
Lipids also play an important role in the fetal development but knowledge about lipid 
transfer to placenta are very inadequate (Herrera, 2002).  The altered  availability of 
lipid components are known to affect the fetal development (Herrera, 2002).  These 
findings have proven that the most important role of lipid metabolism in pregnancy is 
on fetal growth and outcome, inspite of the lack of clear knowledge about lipid 
transfer across the placenta.   
 
1.11 Maternal Hyperlipidemia 
Maternal hypertriglyceridemia is an important distinguishing feature during late 
gestation (Knopp et al., 1992).  The maximum increase in triglycerides in plasma 
directly corresponds to VLDL triglycerides, which are synthesized in the liver 
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(Alvarez et al., 1996).  In addition to their enhanced production in the liver (Wasfi et 
al., 1980), and their removal from the circulation is decreased, as a result of 
decreased activity of LPL in adipose tissue further contributes to their increase levels 
in plasma (Martin-Hidalgo et al., 1994).  The increases in both plasma estrogen 
levels and insulin resistance occuring during late gestation are two main hormonal 
factors responsible for these changes in metabolism that results in the development 
of maternal hypertriglyceridemia.  The insulin resistance which is normally present 
during late gestation contributes to enhanced lipolytic activity of adipose tissue, 
which results in the production of NEFA as well as glycerol to the liver and their 
conversion into triglycerides which are then released back into the circulation as 
VLDL (Ramos and Herrera, 1995).  The increase in estrogen levels throughout 
gestation contributes to maternal hypertriglyceridemia (De Hertogh et al., 1975).   
 
1.12 Role of Maternal hypertriglyceridemia in fetus  
Pregnancy is characterized by an increase in the concentration of lipids which 
present throughout pregnancy.  The concentrations of plasma triglycerides and 
cholesterol increase by 30-50% and 200-400% respectively.  In maternal obesity, the 
hyperlipidemia is increased further with higher triglycerides and VLDL 
concentrations, lower HDL cholesterol, LDL and total cholesterol concentrations in 
the serum appear similar than lean pregnant women (Merzouk et al., 2000, Ramsay 
et al., 2002).  Triglycerides do not crosses the placental barrier directly (Herrera, 
2002), although the essential fatty acids which are obtained from diet intake by 
mothers are transported as triglycerides rich lipoproteins in maternal plasma  
(Herrera, 2002).  The plasma lipoproteins in maternal triglycerides are then 
hydrolysed and carried up by the placenta and then reesterified as fatty acids 
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(Coleman and Haynes, 1987).  After hydrolysis of glycerides, the fatty acids are 
diffusely released to fetal plasma, where they are bind to α-fetoprotein, a specific 
oncofetal protein (Benassayag et al., 1997).  These fatty acids are then rapidly 
transported to liver in fetus and reesterified, released back as triglycerides into fetal 
circulation.  The maternal hypertriglyceridemia plays an important role in the 
availability of esssential fatty acids (EFA) to the fetus.  Kitajima et al (Kitajima et 
al., 2001) has found that there exists a direct association between maternal  
triglycerides in plasma and newborn bodyweight.  Moreover, a reduction in maternal 
hypertriglyceridemia could be achieved with the treatment of hypolipidemic drugs 
which in turn resulted in negative drawbacks in the development of fetus (Hrab et al., 
1994, Soria et al., 2002). 
 
1.13 Maternal obesity and inflammation  
Pregnancy and obesity are related with changes in insulin resistance and 
inflammation (Hotamisligil and Spiegelman, 1994).   Due to obesity, the placenta has 
exaggerated inflammatory response because of the structurally similar inflammatory 
transcriptomes of the adipose tissue and placenta  (Kern et al., 2001).  Obesity is a 
low grade inflammatory condition in nonpregnant women which increases the pro-
inflammatory production from the macrophages in the adipose tissue (Kern et al., 
2001, Zhang et al., 2002).  When the pregnancy is complicated by maternal obesity 
and GDM, the placenta releases cytokines as well as adipocytokines (Bruun et al., 
2003, Hotamisligil and Spiegelman, 1994, Kern et al., 2001, Zhang et al., 2002, 
Mohamed-Ali et al., 1997). 
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There are some changes in both biochemical markers and inflammatory cells in 
maternal obesity, which is considered to be a chronic as well as sub-acute 
inflammation state result in diseases like preeclampsia and gestational diabetes.   
There is a continuous undesirable stimulus in maternal obesity due to dysregulation 
of inflammatory, vascular and metabolic pathways by increased circulation of 
inflammatory molecules.  There arises a question whether obesity in pregnancy 
induced inflammation in the placenta might play a pathogenic role in the 
development of pregnancy linked diseases. The characteristic of the inflammation 
arising in placenta is related to maternal obesity, which still needs further research. 
1.14 Clinical Complications of Maternal Obesity in pregnancy 
1.14.1 Early pregnancy 
Maternal obesity has increased risk for spontaneous abortion (miscarriage) for both 
spontaneous and through assisted reproductive conceptions like in vitro fertilization 
(IVF).  Maternal obesity is also related to an increased risk factor for congenital 
anomalies such as neural tube defects (NTD), spina bifida, congenital heart disease 
and omphalocele in the offspring (Catalano and Ehrenberg, 2006, Waller et al., 1994, 
Watkins et al., 2003, Rasmussen et al., 2008). 
 
1.14.2 Late pregnancy 
Maternal obesity is linked with an increased risk of developing pregnancy induced 
complications like hypertensive disorders of pregnancy, including preeclampsia 
(gestational proteinuric hypertension) (Weiss et al., 2004).  The increase in risk of 
developing preeclampsia is two-fold with increase in BMI of 5-7 kg/m
2
 (O'Brien et 
al., 2003).  Maternal obesity has an increase risk with intrauterine fetal demise 
(stillbirth).  Several studies has reported that  pregnant women with obesity have an 
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increased jeopardy of stillbirth almost doubled than pregnant women with normal 
BMI  (Chu et al., 2007b).  Maternal obesity is highly related with high risk of 
developing both pre-gestational diabetes and gestational diabetes mellitus 
(Hedderson et al., 2008, Chu et al., 2007a).   
 
1.14.3 Peripartum 
Maternal obesity has an increased risk of developing complications during delivery 
and labour.  As maternal BMI increases, the rate of vaginal delivery decreases 
progressively (Chu et al., 2007c).  The rate of cesarean delivery for women with 
normal BMI was 18%, whereas it was 39.6% in morbidly obese women (Ehrenberg 
et al., 2002).  Carroll et al study has revealed that attempted vaginal birth after 
cesarean (VBAC) success rate was 81.8% in women who weighed less than 200 lb 
versus with 57.15 in women who weighed 200-300 lb and it was 13.3% in women 
with more than 300 lb (Carroll et al., 2003). 
 
There is also an increased risk of operative delivery for obese women which results 
in intraoperative complications like increased wound infections and 
thromboembolism (Soens et al., 2008).  The cause of the increased rate of cesarean 
delivery in obese pregnant women is not clearly understood.  However, Vahratian et 
al found that this increase in cesarean rate in obese pregnant women might be due to 
dysfunctional labour (Vahratian et al., 2004).  Maternal obesity in first trimester were 
associated with increased risk of reduced rate of spontaneous labour at term which 
results in post term pregnancy and intrapartum complications (Denison et al., 2008) 
 
1.15 Implications of maternal obesity on fetal/neonatal complications 
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1.15.1 Fetal Macrosomia-Adverse outcome of maternal obesity 
Maternal obesity is highly associated with abnormal growth in the fetus. The fetal 
macrosomia which is a major outcome in maternal obesity, which is distinct with 
estimated fetal weight equal to or more than 4500g and found to be increased to two-
three fold in pregnant women with high body mass index (Ehrenberg et al., 2004).   
Chu et al, in their meta-analysis reported that prevalence of fetal macrosomia were 
14.6% and 13.6% for morbidly obese and obese women respectively versus 8.3% for 
normal weight pregnant women (Chu et al., 2007b).  The babies of GDM mothers 
have increased fetal fat mass (Sparks, 1984, Catalano et al., 2003b), as do the babies 
of women who are obese but not diabetic (Chu et al., 2009, Sewell et al., 2006) 
suggesting that hyperglycaemia, might be an important  driver for intrauterine 
growth. 
There are however, some caveats to the hypothesis that hyperglycaemia alone acts as 
a driver for intrauterine growth. A large proportion of women with diabetes, who 
maintain excellent glycaemic control, continue to have a macrosomic fetus of about 
3.5 times higher risk than the general population (Evers et al., 2002, Murphy et al., 
2008), which appears to be a function of the pregravid BMI (Langer et al., 2005).   
This finding is highlighted when considering that an overweight woman with well 
controlled GDM has a 50% higher chance of having a macrosomic baby compared to 
a lean woman with well-controlled GDM.  
Obesity therefore, independently of diabetes,  predisposes to fetal macrosomia 
(doubling the risk without diabetes) (Langer et al., 2005).   While it is known that the 
increase in fetal macrosomia represents an increase in fetal fat mass, how the 
maternal environment enhances this lipid deposition in fetal tissues, either in the 
absence of diabetes (as in obesity) or in well-controlled diabetes, is not completely 
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understood.   Sparks et al  (Sparks, 1984) has  hypothesized that genetic factors is 
related to fat-free mass (FFM), whereas in utero environment  may also related to 
fetal fat mass,  in agreement with the fetal origins of disease hypothesis,  the 
offspring of both GDM and obese women have increased risks of obesity and type 2 
diabetes (Stothard et al., 2009, Garcia-Vargas et al., 2012). 
 
1.16 Literature Review for Offspring 
1.16.1 Barker hypothesis 
In utero fetal programming hypothesis or Barker hypothesis (Barker, 1990),  the  
birth size is related to developing disease in later life.   The Barker hypothesis was 
originally studied on low birth weight.  There are some studies revealed that high 
birth size may also have complications later in life.   A relationship between maternal 
obesity during the first trimester and childhood obesity has been reported.   Whitaker
 
(Whitaker, 2004
)
  reported that high risk of developing childhood obesity has been 
related with maternal obesity in the first trimester of pregnancy was 2.0 at 2 years,  
2.3 at 3 years,  and 2.3 at 4 years.   There has been a direct association between the 
birth weight and body mass index in later life (Oken and Gillman, 2003).  
When there is an insufficiency or surplus of nutrients supply to the placenta, the 
acquired adaptations of the fetuses may reflect change in physiology and metabolism 
permanently (de Boo and Harding, 2006).   The root cause of various diseases that 
occur in later life, including hypertension, heart disease and non–insulin dependent 
diabetes might be due to these changes in fetal programming.  Obesity may become a 
significant long term problem due to fetal programming.   Daughters of obese 
mothers may be susceptible to obesity and further liable to have children with obesity 
who have again this susceptibility creating a vicious cycle.  
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1.16.2 “Metabolic Memory” 
According to the fetal origin hypothesis, during pregnancy the fetal malnutrition 
affects fetal growth which leads to thinness at birth, metabolic syndrome and type 2 
DM (Hales and Barker, 2001).  Hales and Barker hypothesis has suggested that 
during the process of fetal development, there might be some long term impacts on 
fetus due to a stimulus, which was described previously as “fetal programming” 
(Hales and Barker, 2001), is now defined as “metabolic memory”.   In an intrauterine 
diabetic environment, the fetal programming is termed as “metabolic memory”.   
Obesity in pregnancy has a relative high risk of developing obesity and diabetes in 
the fetus in adulthood.  Moreover, pregnant women with gestational diabetes could 
possibly show evidence of greater fetal macrosomia than pregnant women with 
obesity (Cox, 1994).  Both maternal obesity and GDM have their own obstetric 
complications.   
This metabolic memory seems to cause physiological anomalies during gestational 
period which are liable for the diseases in fetus in later life such as obesity and type 2 
DM allied with metabolic syndrome (Dorner and Plagemann, 1994).  According to 
this metabolic memory phenomenon, Palinski and Napoli (Palinski and Napoli, 
2002) have shown that maternal hypercholesterolemia is linked with increase in the 
formation of fatty streak in fetal arteries which enhances the childhood 
atherosclerosis (Palinski and Napoli, 2002).  There exists a relationship between 
maternal and fetal cholesterol levels in human plasma in 5-6 month fetuses (Napoli et 
al., 1997, Vogel et al., 1997).  Furthermore, maternal hyperglycemia might lead to 
fetal hyperglycemia has been found to stimulate pancreatic islets cells in fetus to 
produce fetal hyperinsulinemia (Schwartz and Teramo, 2000). 
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1.17 Studies on Maternal Obesity  
 
During pregnancy, the association between obesity and inflammation has been 
detailed by a number of studies.   Challier et al  (Challier et al., 2008) found higher 
circulating  pro-inflammatory cytokines, secondary to production of peripheral  
mononuclear cells in maternal blood, which has revealed higher production of TNF 
and IL6 mRNA expression.  Ramsay et al. 2002 (Ramsay et al., 2002), reported that 
the leptin, and IL6 levels in serum were elevated in obese women compared with 
lean women.  A recent study has found that the maternal obesity was associated with 
infiltration of macrophage into adipose tissue (Farley et al., 2009).  Challier et al 
(Challier et al., 2008) studied that there is an increase in proinflammatory cytokines 
in peripheral blood mononuclear cells in pregnancy.  Boomsma et al (Boomsma et 
al., 2006) study has revealed that there is a link between obesity in pregnancy and 
adverse pregnancy outcome and also found that intolerance in glucose and insulin 
resistance both would mediate adverse pregnancy outcome due to obesity.  A study 
by Kirwan et al (Kirwan et al., 2002), reported that TNF was an interpreter of insulin 
resistance in lean pregnant women in late gestation, when compared to non-obese 
women with gestational diabetes.   
Stewart et al studied that higher ICAM-1 and lower plasminogen activator inhibitor 
in serum of obese women compared with lean pregnant women (Stewart et al., 
2007).   Metzger et al (Metzger, 1991) has studied that women with polycystic 
ovarian syndrome has intolerance in glucose and insulin resistance.  Ramsay et al 
and Martin et al (Ramsay et al., 2002, Martin et al., 2009), has studied that 
abdominal obesity are linked with glucose intolerance and insulin resistance, which 
results in gestational diabetes which is more common in pregnant women with high 
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BMI.   Colomiere et al has identified the defects in the insulin-signaling cascade in 
obese pregnant women with normal glucose tolerance in both skeletal muscle and 
adipose tissue (Colomiere et al., 2009).    
 
1.18 Studies on maternal obesity outcomes 
There are numerous studies on maternal obesity outcome, which has long term 
implication on the offspring.  Maternal BMI is positively correlated with childhood 
obesity (Jensen et al., 2003, Singhal and Lucas, 2004, Oddy et al., 2006).   Danielzik 
et al (Danielzik et al., 2002) has reported the relationship between offspring BMI and 
paternal BMI has proved that it does not shown to be as strong as the maternal 
association.   Burdette et al (Burdette et al., 2006) has shown that  offspring of obese 
mothers have 0.54 kg more fat mass than offspring of non-obese mothers.  Knight et 
al (Knight et al., 2007) showed that maternal BMI is related with offspring weight at 
birth, 1 year and 2 years and also shown that prepregnancy BMI correlated with 
offspring obesity during the first 2 years of life and after 1 year post-birth offspring 
obesity has been also correlated with paternal BMI.  O'Callaghan et al (O'Callaghan 
et al., 1997) reported that pre-pregnancy maternal obesity and paternal obesity  are 
self-determining predictors of severe obesity at 5 years.   
Parson et al (Parsons et al., 2001) reported that pre-pregnancy maternal obesity might 
explain the relationship between birth weight and adulthood obesity.  Whitaker et al 
(Whitaker, 2004) showed that the childhood obesity has more risk at 4 years was 
linked with maternal obesity during first trimester.   Salsberry et al (Salsberry and 
Reagan, 2005, Li et al., 2005) has shown that pre-pregnancy BMI is related with an 
increased overweight odds ratio in the offspring.  Blair et al (Blair et al., 2007) has 
also shown that maternal obesity results in offspring obesity.  Lawlor et al (Lawlor et 
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al., 2007) has studied that pre-pregnancy maternal BMI has proved to be a high risk 
for offspring obesity than paternal BMI.  Danielzik et al (Danielzik et al., 2002) has 
reported that childhood BMI has been significantly related with parental BMI, 
though a closer correlation was observed between maternal than paternal BMI.   
Koupil and Toivanen (Koupil and Toivanen, 2008) also reported that maternal pre-
pregnancy BMI was proved to be the strongest predictor of offspring obesity. The 
maternal IDDM which has diagnosed after has significantly high risk of developing 
childhood obesity and IDDM compared to the siblings born before the diagnosis of 
maternal IDDM (Dabelea et al., 2000).  Similarly, the pattern of growth of fetus and 
infant adiposity mass at birth, 6 weeks and 6 months post partum was studied by Ay 
et al (Ay et al., 2009) and suggested that the obesity risk is established in fetal life in 
later life.  Children of mothers with obesity are susceptible of developing obesity 
even if they are born with normal birthweight.  Dabelea et al (Dabelea et al., 2000) 
has reported that  obese women who delivers children of normal birth weight will 
become as overweight,  obese or morbidly obese (88%) compared to children  born 
to lean women (13%).  These studies have suggested that pre-pregnancy BMI and 
gestational obesity might be a initial key step in a multifactorial process which 
extends from mother to the child. 
 
1.19 Gestational diabetes (GDM) 
Gestational diabetes can be defined as any degree of glucose intolerance with the 
first onset or recognition during pregnancy
 
(Hillier et al., 2008, Callaway et al., 
2006).   Clinically, GDM manifests, when about 70% of fetal growth occurs in late 
gestation.   Based on the screening and diagnostic criteria, the prevalence of GDM 
ranges from 1.3% to 19.9% (Simmons, 2011).  An increase in maternal obesity is a 
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well-known risk factor for gestational diabetes.  There is an increased risk of 
developing GDM in obese pregnant women than lean pregnant.   An obese woman 
has three to ten times of higher rates of preexisting gestational diabetes mellitus and 
hypertension (Sebire et al., 2001, Kumari, 2001).  In a meta-analysis study  has 
shown that the risk of increasing gestational diabetes was 2.14-fold greater in 
pregnant women who were overweight, 3.56-fold greater in obese pregnant women 
and  9-fold  greater in pregnant women with grade 3 obesity compared to lean 
pregnant women (Sebire et al., 2001).   
The incidence between gestational diabetes and obesity has strong association.  It is 
predictable that in the absence of obesity, the occurrence of gestational diabetes may 
fall by 50% approximately (Jensen et al., 2003).   The risk of increasing gestational 
diabetes is strongly predisposed to preexisting maternal BMI (Weiss et al., 2004, Bo 
et al., 2004).  In obese pregnant women, the fasting levels of insulin are found to be 
higher than non obese pregnant women (Catalano et al., 2003a).  Insulin resistance is 
already higher in obese women before conception without any clinical symptoms 
(Catalano et al., 2003a).  In obese pregnant women, insulin levels are increased in an 
attempt to maintain normoglycemia.  However, this is not possible, as the usual 
increase in insulin resistance during pregnancy is overstated in obese women.   
The risk of developing GDM in overweight women is 6.5 times higher than non-
obese women.  However, the incidence of GDM in obese women is 1.4–20 times to 
percentage between 6-11% (Galtier-Dereure et al., 2000, Glazer et al., 2004).  The 
incidence of gestational diabetes in morbidly obese women is 9.5 % compared to 
2.3% in nonobese pregnant women (Weiss et al., 2004).  Similarly, the incidence of 
GDM is 24.7% in morbid obese women (Kumari, 2001). 
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In early pregnancy, the glucose levels in fasting state cannot be used to predict GDM 
(Bhattacharya, 2004).  However, by measuring the fasting glucose concentrations in 
plasma in the second half of pregnancy, it is possible to identify GDM in 70% of 
women (Perucchini et al., 1999).  Moreover, it is worthwhile to screen obese women 
in antenatal clinic during first visit for subclinical hyperglycemia.  There is an 
increased jeopardy of developing preeclampsia in women with GDM.  In this 
relationship, obesity is considered as a major contributing feature (Ostlund et al., 
2004, van Hoorn et al., 2002).    
A new criteria for the diagnosis of GDM based on Adverse Pregnancy outcomes 
(HAPO) and hyperglycemia study has been proposed by the International 
Association of Diabetes and Pregnancy Study Groups (IADPSG)  (Metzger et al., 
2010).  The diagnostic criteria for GDM is without prior glucose challenge, use of 
75g oral glucose tolerance test (OGTT), when the glucose at fasting state is ≥5.1 
mmol/L and /or when 1 hr postload glucose is ≥10.0 mmol/L and /or when 2 hrs 
postload glucose is ≥8.5 mmol/L (Metzger et al., 2010).  The diagnostic criteria of 
WHO for GDM are  glucose at fasting state is ≥7 mmol/l or 2 hr glucose ≥ 7.8 
mmol/l (Alberti and Zimmet, 1998).  However, to diagnose GDM, 1-hr postprandial 
plasma glucose test is considered as a perfect screening method  with high sensitivity 
and specificity (Hidar et al., 2001).  In obese and overweight women with gestational 
diabetes or impaired glucose tolerance, the outcomes in both maternal and fetal were 
not only poor but also in obese pregnant women, who have good criteria for 
normoglycemia following a 75 g oral glucose tolerance test (OGTT) has also poor 
outcomes (Jensen et al., 2003, Owens et al., 2010). 
Gestational diabetes mellitus has considered carrying health risks for both the mother 
and the fetus (Coustan and Carpenter, 1998).  Gestational diabetic women will return 
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to normoglycemic level after delivery and it is well recognized that glucose 
intolerance detected during pregnancy is a definite predictive of developing maternal 
type 2 DM in later life (Metzger, 1991, Kjos and Buchanan, 1999).  GDM mothers 
have an increased possibility of developing Type 2 Diabetes mellitus in later life 
(Henry and Beischer, 1991).   
 
1.20 Pedersen Hypothesis 
The Pedersen Hypothesis proposes that in the poorly controlled maternal diabetes 
mellitus, both over nutrition as well as fetal hyperglycaemia will cause poor  fetal 
outcomes, suggested that the extreme mobility of carbohydrate across the placenta 
would increase relative  hyperglycaemia and in turns the compensatory 
hyperinsulinaemia in the fetus (Pedersen, 1971).   It is now recognized to produce a 
twofold increase in developing macrosomia due to fetal hyperinsulinaemia (Pedersen 
and Molsted-Pedersen, 1978). 
 
1.21 Fetal Macrosomia-main adverse outcome of GDM
 
Diabetes in pregnancy is well characterized by an increased glucose transport and 
other essential nutrients to the placenta from mother to the fetus which results in fetal 
macrosomia (Van Assche et al., 2001).  Several studies have reported that either type 
1 DM and type 2 DM (preexisting diabetes) or gestational diabetes (GDM) is related 
with fetal macrosomia (Evers et al., 2004, Giordano, 1990, Ategbo et al., 2006, 
Mitanchez, 2010, Dorner et al., 1987, Pettitt et al., 1988). Gestational diabetes and 
Type 2 DM are also linked with fetal macrosomia and diabetes in offspring (Dorner 
et al., 1987).  The risk of developing diabetes in fetus is significantly higher when 
maternal type 2 diabetes is present rather than  paternal diabetes (Dorner et al., 1987, 
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Pettitt et al., 1988).  However, the risk of developing insulin resistance is much 
higher in children of GDM mothers than in children of mothers who develop diabetes 
after pregnancy (Pettitt et al., 1988).    
The adverse outcome of maternal diabetes which is commonly seen is fetal 
macrosomia (Mitanchez, 2010).  About 43% of  GDM mothers will have a 
macrosomic history has been estimated by several human studies (Ategbo et al., 
2006, (Grissa et al., 2007).   
 
1.22 Alteration in lipid metabolism in GDM  
In accordance with WHO (World Health Organisation) criteria, GDM  could be 
detected by the oral glucose tolerance test and several human studies have revealed 
diabetes during the second or third trimester of pregnancy (Grissa et al., 2007).  
Several studies have revealed that both control pregnant women and GDM mothers 
had hypertriglyceridemia and hypercholesterolemia during pregnancy (Ategbo et al., 
2006, (Grissa et al., 2007).  Moreover, macrosomic babies had higher levels of serum 
total and free cholesterol as well as triglyceride  compared with control babies 
(Ategbo et al., 2006, (Grissa et al., 2007, Toescu et al., 2004).  These studies have 
revealed that diabetes in pregnancy and macrosomia will provoke an alteration in the 
metabolism of lipids. 
 
1.23 Common adverse effects associated with maternal obesity and GDM 
Obesity epidemic is common among children, adolescents, young adults and elderly 
adults (Guelinckx et al., 2008, Caballero, 2005).  Subsequently, the number of 
pregnant women with high BMI is also increasing.  The epidemic of obesity is 
explained by the high consumption of energy rich foods and a lack of physical 
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activity.  Besides, there are many other factors which might explain the flare-up in 
the prevalence of obesity (McAllister et al., 2009).  These additional factors work 
through genetic factors, reproductive behaviours and intrauterine environment, which 
is important for  maternal obesity and gestational diabetes (McAllister et al., 2009). It 
is well understood that obesity is directly connected to high adiposity and 
hyperlipidemia (Dandona et al., 2004).  However, besides peripheral adiposity, 
central fat is more linked to insulin resistance and is a predisposing factor to 
gestational diabetes (Carey et al., 1997, Knopp et al., 1992).  
 Recently, several studies have found that increase in weight gain during pregnancy 
in turn increases the birth weight of offspring, thus increases the possibility of 
developing obesity later in life. This is independent of genetic factors (Ludwig and 
Currie, 2010).  Furthermore, maternal obesity was significantly related to 
complications on both mother and baby (Roman et al., 2011) and leads to gestational 
diabetes, pregnancy related hypertension and cesarean delivery and increase risks of 
developing stillbirth, macrosomia, hypoglycemia, shoulder dystocia, and jaundice 
(Roman et al., 2011).  Moreover, recent studies have strongly supported occurrence 
of  fetal macrosomia due to GDM (Mitanchez, 2010) and despite the consequences 
of diabetes status, obesity is an additional risk factor for further complications in 
pregnancy (Mitanchez, 2010).  There are still some differences between GDM and 
maternal obesity, as GDM mothers have greater incidence of having fetal 
macrosomia even after treatment and greater risk of developing jaundice and 
neonatal hypoglycemia in the babies of GDM mothers than obese mothers, besides 
some women may have undiagnosed preexisting diabetes mellitus (Simmons, 2011). 
1.24 Scientific background 
1.24.1 Biology of Adipose tissue 
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Lipid is important as a nutritional depot, having hormonal role, and in providing 
structural support.  Adipose tissue is the body’s main fat depots, and is a highly 
active organ and contains adipocytes.   The adipocytes are cells particularly adapted 
for fat storage, which help to avoid the negative metabolic effects of excess 
deposition of lipid in organs such as muscle, liver, and heart. The adipose tissue 
contains a connective tissue matrix, with numerous fibroblasts, mast cells, 
macrophages, and leukocytes (Fain, 2006).  Numerous peptides and steroid 
hormones as well as the cytokines and chemokines, synthesized and secreted by 
adipose and non fat cells, which influence local and systemic physiology (Fain, 2006, 
Kershaw and Flier, 2004).   Additionally, it functions as an endocrine organ 
(Kershaw and Flier, 2004) that causes pathology linked to obesity.  It also stores and 
secretes preformed steroid hormones, which induce the conversion of biologically 
active hormones from their precursors, and also convert the active hormones to 
inactive metabolites.   They also secrete numerous enzymes vital to steroid hormones 
(Kershaw and Flier, 2004).  
 
1.24.2 Types of adipose tissues 
In White adipose tissue (WAT), the triglyceride is stored; and lipids are mobilized 
for the other tissues for the systemic consumption for energy (Weisberg et al., 2003).   
WAT commonly presents as subcutaneous and abdominal depots; they are distinct in 
their physiologies, and actions in pathology (Xu et al., 2003).  In contrast, brown 
adipose tissue, is thought to be involved in the process of heat production through the 
uncoupling of oxidative phosphorylation, called non-shivering thermogenesis.  An 
integral membrane protein, named the uncoupling protein-1, located in the 
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mitochondrial inner membrane, regulates the thermogenic proton leak in brown 
adipose tissue (Krauss et al., 2005). 
 
1.24.3 Cytokines  
 A large number of peptides have been secreted by white adipose tissue (WAT).    
They were initially well-defined as metabolic regulators, and were later found to 
adapt inflammatory processes, for example interleukin (IL)-6, IL-1 and its receptor 
antagonist (IL-1Ra), and leptin, adiponectin and tumour necrosis factor (TNF)-α  
(Hansson, 2005). These immuno-modulatory factors which are adipose derived, in 
which both the cytokines and chemokines play an important role in chronic vascular 
inflammatory process (Hansson, 2005).   Consequently, the various peptides which 
are secreted by adipose tissue have acknowledged extensive attention.  
More than 100 different cytokines are well recognized at this current period.  
Cytokines are identified to be implicated in many biological processes, together with 
growth, differentiation, immunity, inflammation, cell division and apoptosis which 
are classified as chemokines,  haematopoietic factors, interleukins, interferons, and 
growth factors (Hansson, 2005).  They are identified to be bioactive even at very low 
concentrations, for instance even 10% of receptor  is  adequate to activate a response 
(Oppenheim, 2001). 
 
 1.24.4 Adipokines 
A large variety of proteins identified as adipokines are secreted in adipose tissue 
which controls diverse metabolic functions through various pathways like auto, para, 
or endocrine.  Out of more than 50 adipokines identified,  leptin and adiponectin  
have been extensively researched (Gavrilova et al., 2000). 
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1.25 ADIPSIN 
1.25.1 Identification of Adipsin 
Adipsin (ADIPocyte-trypSIN) was originally identified as a 28-kDa adipocyte 
secreted protease with homologous to complement D in human.  Adipsin was first 
identified by Spiegelman et al (Spiegelman et al., 1983) in the mouse cultured 
adipocyte cell line (3T3-F442A) as mRNA on the basis of  differentiation-dependent 
expression.  Cook et al (Cook et al., 1985) identified adipsin as a novel serine 
protease. Adipsin, a serine protease or complement factor D, was described first as 
an adipocyte derived endocrine factor in 1986 (Min and Spiegelman, 1986).  Later, it 
has been identified in murine 3T3-F442A adipocytes together with complement C3, 
D and B (all three important components of the alternative pathway) (Esterbauer et 
al., 1999, Peake et al., 1997). Adipsin protein was subsequently found in adipose 
tissue and reported as serine protease (Min and Spiegelman, 1986).  It was 
subsequently found to be homologous to complement D, which plays as a key 
enzyme in the regulation of the alternative complement pathway (Rosen et al., 1989).  
Choy and Spiegelman et al have explained that there might be an association 
between the adipose tissue metabolism and activation of the alternative complement 
pathway (Choy et al., 1992, Choy and Spiegelman, 1996).  Adipsin was first 
described as an adipokine (Cook et al., 1987) before being identified in muscle (Zhu 
et al., 1994), lung, peripheral nerves (White et al., 1992) and more recently in the 
murine placenta (Takeshita et al., 2010). 
 
1.25.2 Role of Adipsin 
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 The precise function of adipsin in adipose tissue remains still uncertain. Flier et al 
(Flier et al., 1987) that adipsin protein expression was severely impaired  and also 
circulating adipsin protein was decreased in both acquired and genetic models of 
obesity in rodents.   But in these “cafeteria models” of rats (which obtained obesity 
by overfeeding), the expression of adipsin showed only a little change (Flier et al., 
1987) and suggested a possible role of adipsin in metabolic disorders like obesity.  
Moreover, the study about drug induced obesity and genetic (db/db,fa/fa and ob/ob) 
revealed that mRNA adipsin levels in adipose tissue as well as adipsin concentrations 
in plasma were found to be reduced (Choy et al., 1992).  In contrast, in humans, 
adipsin levels were increased in a positive correlation with BMI.  It is therefore 
possible that adipsin may play a role in adipose tissue lipid metabolism indirectly 
(Maslowska et al., 1999).  There were several other adipose tissue derived 
complement components, which have considered previously unsuspected links 
between immunity and energy balance in addition to adipsin.  Factor b as well as 
Complement C2, C3, C4, C7 has increased expression in omental than subcutaneous 
adipose tissue.  Moreover, adipsin and components of classical pathway C1QB, C1R 
and C1S were expressed in both adipose tissues (Gabrielsson et al., 2003).  
Napolitano et al  has measured adipsin concentration in serum of both lean and obese 
humans, and found it to be elevated in circulating levels in serum of obese than lean 
individuals (Napolitano et al., 1994).  The  alternative complement pathway is 
activated which  results in the interaction of complement C3 and adipsin, with 
activated factor B, resulting in the protein C3 cleavage  into C3a and C3b and results 
finally in the desaggregation of C3a to produce C3adesArg- Acylation stimulating 
protein (ASP) (Cianflone et al., 1994).   Interestingly, adipsin is the rate limiting 
enzyme in the formation of Acylation stimulating protein (ASP) (Baldo et al., 1993).  
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ASP is an adipose tissue secreted factor that manipulates the rate limiting step in 
synthesis of triacylglycerol (TG) in adipose tissue (Cianflone et al., 1994).  In 
addition to this, ASP increases transport of glucose through translocation of glucose 
transporters (GLUT-1, GLUT-3 and GLUT-4) (Maslowska et al., 1999).   
 
1.26 Acylation stimulating Protein 
There has been an increasing interest in Acylation stimulating Protein (ASP), which 
is 76-amino acid protein, and found to be one of the controlling factors in adipose 
tissue function in modern years.   ASP has been determined to be the complement C3 
derivative and was first identified in the human plasma (Cianflone et al., 1989). 
Complement C3 has been related to insulin resistance, obesity, dyslipidaemia and 
CHD (coronary heart disease).  Complement C3 is cleaved to form ASP or Acylation 
stimulating protein or C3adesArg by a cascade of enzymes, which is mostly 
regulated by adipsin. ASP is a strong stimulator in the synthesis of triglyceride in 
adipocytes (Cianflone et al., 1994).  
 
1.26.1 Identification of ASP 
Acylation stimulating protein is 8.9 kDa hormone which is formed through an 
interaction of complement C3 in which arginine removal from activated C3 (C3a) by 
carboxypeptidase, C3a together with factor B and factor D (Adipsin) which forms 
C3adesArg in the adiocytes (Cianflone et al., 1994).   ASP is formed through the 
interaction of complement C3 with factor B and factor D (adipsin) through a two 
steps (Fig 1.1) 
1) Cleavage of complement C3 (parent protein) to produce C3a 
2) Carboxyl terminus is desarginased to produce ASP (C3adesArg) 
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Several studies recently have reported that human fat cells have mRNA for 
complement factor D, a serine protease enzyme (Adipsin), cofactor B and C3, all of 
these components are necessary to generate C3a which is a precursor for ASP.  In 
numerous studies, it has been studied that adipocytes express and also secrete mRNA 
for all three factors in a differentiation dependent manner (Cianflone et al., 1995b, 
Choy and Spiegelman, 1996, Peake et al., 1997).  It has also been demonstrated that 
basal ASP is produced in the cultured adipocytes (Cianflone et al., 1995b, Choy and 
Spiegelman, 1996, Peake et al., 1997) with an increase in the ASP production after 7 
days of adipocyte differentiation.   
ASP is also produced in the alternate complement pathway by the interaction of 
complement C3, factor B and factor D (adipsin) and can also be produced by the 
classical complement pathway as well as the lectin pathway (Sniderman and 
Cianflone, 1994).  Carboxypeptidase B is present in plasma at high levels and 
produced in many cells including fibroblasts.  Complement C3a receptor has been 
identified recently (Ames et al., 1996, Crass et al., 1996) and cloned in human (Ames 
et al., 1996), mouse (Crass et al., 1996, Tornetta et al., 1997) and rat (Fukuoka et al., 
1998).  ASP is known to bind saturably specific to omental and subcutaneous 
adipocytes (Saleh et al., 1999), preadipocytes (Murray et al., 1997) and fibroblasts 
(Zhang et al., 1998) in murine and human cells despite a lack of C3a receptor protein 
or mRNA in adipose tissue (Saleh et al., 1999). 
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Fig.1.1 Formation of ASP (Acylation Stimulating Protein) 
 
 
 
 
 
 
 
1.26.2 Actions of ASP 
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ASP has been identified to enhance the synthesis of triglyceride and storage in 
adipocyte in association with  diacylglycerol acyltransferase-2 (DGAT2) stimulation 
and glucose uptake and inhibition of hormone sensitive lipoprotein lipase (HSL) 
through phosphodiesterase and released into the circulation (Cianflone et al., 1999, 
Sniderman et al., 2000, Van Harmelen et al., 1999) and thus ASP contributes to 
energy storage as lipids (Fig 1.1).  This was confirmed in a study by Murray et al 
(Murray et al., 1999a) who showed that the administration of ASP to mice increases 
clearance of triglycerides from the plasma.  It has also been confirmed that ASP 
deficient mice (C3-/-) have delayed clearance of lipids postprandially and have 
reduced depots in adipose tissue which are obesity resistant provoked by high fat diet 
(Murray et al., 1999b, Murray et al., 2000).  While ASP increases lipogenesis in the 
adipose tissue through the activation of DGAT2, it also reduces lipoprotein lipase 
activity, thereby decreasing triglyceride breakdown (Yasruel et al., 1991, Van 
Harmelen et al., 1999), which results in ASP-driven enhancement of lipid storage in 
the adipose tissue (Cianflone et al., 1994, Millar et al., 2000).  The concentrations of 
ASP in the human plasma in normal adults range from 10-58 nM which no related 
gender differences (Maslowska et al., 1999).   
ASP release in adipose tissue increases at 4-5 hrs postprandially after intake of meal, 
but the circulating levels stay constant (Saleh et al., 1998). Studies have revealed that 
the ASP levels in plasma are increased in obesity (Weyer and Pratley, 1999) and 
reduced in fasting (Cianflone et al., 1995a) and in post-obese women (after bariatric 
surgery) (Faraj et al., 2001).   
In human adipocytes and skin fibroblasts, ASP increases the synthesis of triglyceride 
by inducing the incorporation of fatty acid into adipose triglyceride (Cianflone et al., 
1999).  The triglyceride synthesis stimulation by ASP is more effective than insulin 
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and synergistic with the combined effect of insulin and ASP with re-esterification 
and fatty acid storage (Cianflone et al., 1994).   
 
1.26.3 Identification of ASP receptor 
Recently, the ASP receptor, C5L2, has been identified in ASP responsive cells 
(Kalant et al., 2005).  Since the identification of the ASP receptor, the physiological 
role of ASP has drawn more interest on its research.  Marcil et al (Marcil et al., 2006) 
has studied a French Canadian family and shown that a variant of the ASP receptor 
was associated with increased total cholesterol, low density lipoprotein-cholesterol 
(LDL-C), triglycerides, apoprotein B and acylation stimulating protein.  These study 
subjects also shown a reduction of about 50% ASP stimulated triglyceride synthesis, 
glucose transport and significant reduction in ASP binding compared with the 
controls which suggested malfunction of receptor (Marcil et al., 2006).  This 
hyperlipidemic milieu created in these dyslipidemic subjects suggested the 
hypothesis of ASP resistance might possibly due to receptor down regulation. 
 
1.26.4 Role of ASP in Obesity 
A study by Cianflone et al  has demonstrated morbidly obese subjects have higher 
ASP in the fasting state  but in contrast,  the ASP levels increase more post 
prandially than in lean controls (Cianflone et al., 1995a).  ASP levels decreased due 
to weight loss together with a decrease in  ASP precursors (complement C3, factor B 
and adipsin) with weight loss (Muscari et al., 1990).  Obese humans have 60-400% 
increase in ASP above normal and there is a reduction of ASP to normal levels in 
these obese subjects after a 4 week diet state (Kalant et al., 2000).  This suggests that 
higher circulating ASP levels in obese might increase the storage of triglycerides, 
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while adipocytes in the obese remain as sensitive to ASP effects as in lean controls.  
However, ASP induced triglyceride synthesis is not only more effective than 
triggered by insulin, but also appears to be independent and synergistic with insulin 
action (Germinario et al., 1993).  Interestingly, plasma adipsin and ASP levels are 
increased in states of insulin resistance and ASP levels are significantly increased in 
obese individuals (Cianflone et al., 2003, Weyer et al., 2000, Koistinen et al., 2001).  
These contribute to enhance storage of triglycerides in insulin impairment conditions 
(Zimmet et al., 1999, Faraj et al., 2008).  Insulin resistance is a normal state in 
pregnancy and is linked with increase in plasma ASP concentrations in late gestation 
(Saleh et al., 2007).   
 
1.26.5 Role of ASP in Diabetes 
Maslowska et al has studied that the ASP synthesis enhances with increases in 
insulin and both ASP and insulin suppress lipolysis in fatty tissue (Maslowska et al., 
2006).  ASP also stimulates the uptake of glucose in adipocyte significantly in vitro 
studies (Maslowska et al., 2005, Cui et al., 2007).  ASP secretion increased after a 
fatty meal in humans but the concentration of ASP remained constant after an oral 
administration of glucose.  ASP levels were increased in obesity, nephrotic syndrome 
and in metabolic disorders with insulin resistance and dyslipidemia (Saleh et al., 
1998).   Obesity could be a bewildering factor in type 2 diabetes, as in these subjects 
there has been an increase in the levels of ASP, factor B, adipsin and complement C3 
than non-diabetic controls of matched weight (Koistinen et al., 2001).  In non-
diabetic controls, ASP levels correlated with blood glucose and lipids but there was 
no such correlation in diabetic subjects might be due to a dysregulation in the 
production or metabolism of ASP (Koistinen et al., 2001). 
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1.26.6 Role of ASP in other metabolic disorders 
 
Cianflone et al studied HyperapoB subjects  and demonstrated that there has been a 
dysfunction of the ASP pathway and also has higher levels of ASP in plasma of those 
subjects (Cianflone et al., 1990).  This might be probably due to decreased 
responsiveness to ASP at the adipose tissue resulting in a compensatory increase in 
ASP levels.  The levels of C3 mRNA correlate with plasma NEFA, triglycerides and 
leptin and these factors might up-regulate the production of ASP in the insulin 
resistant state (Maslowska et al., 1997).  There was little or no effect on the 
production of ASP with glucose, FFA, VLDL, LDL, and HDL, while insulin 
increases ASP production in a dose dependant manner (Maslowska et al., 1997). 
 
1.27 Studies on Adipsin, C3, factor B and ASP in obesity and diabetes 
There are numerous studies on Adipsin, complement C3, factor B and ASP which 
have examined the association between the precursor proteins like complement C3a, 
factor B and adipsin (factor D) and ASP in plasma.  There are many interesting 
studies about ASP and C3, but there are only few studies on adipsin and factor B.  
Each of these proteins was related to be increased in obesity in many studies, even 
though not in all studies.  For instance, the increase in ASP ranges from 58-400% in 
normal (Koistinen et al., 2001, Maslowska et al., 1999, Weyer and Pratley, 1999, 
Cianflone et al., 1995a), whereas the increases in C3 ranges from 11-25% normal 
(Pomeroy et al., 1997, Muscari et al., 2000, Scriba et al., 1979), the increases in 
adipsin ranges from 14-64% normal (Napolitano et al., 1994, Mavri et al., 1999, 
Maslowska et al., 1999, Alessi et al., 1995).  These studies confirmed that there were 
significant increases in adipsin and C3 with the increases in ASP tending to exist 
higher. This is reliable with the hypothesis suggested that ASP represents an 
40 
 
important bioactive molecule and any changes in adipsin and C3 might reflect on the 
production of ASP.  The link between obesity and complement C3 is not so new 
(Scriba et al., 1979).  In obese Caucasians, ASP was increased more than in obese 
Pima Indians, besides BMI were compared between these two subjects (Weyer and 
Pratley et al., 1999).  Plasma triglycerides and cholesterol was lower in obese Pima 
Indians, but insulin was higher (Weyer and Pratley et al., 1999) as was adipsin 
(Napolitano et al., 1994).  The fasting complement C3 concentration , insulin and 
especially insulin sensitivity were found to be related to adiposity, insulin resistance 
and atherosclerosis (Weyer et al., 2000). 
The complement C3, factor B, ASP and adipsin (factor D) have reported to be 
increased significantly in NIDDM (Type 2 DM) and IDDM (Type 1 DM).  Obesity 
may be a confounding factor which is often associated with diabetes.  When 
compared to non-diabetic groups of matched weight, ASP has been found to be 
increased (Koistinen et al., 2001(Ozata et al., 2001).  The plasma C3 levels are 
increased in non-obese Type 1 diabetes and this is exacerbated by hypertension 
(Mantov and Raev, 1996).  In nondiabetics, ASP has been linked with glucose and 
lipid metabolism but not in diabetics (Koistinen et al., 2001), which has been proved 
that in diabetes, metabolic disturbances has overcame the role of ASP which would 
explain the loss of association (Koistinen et al., 2001). 
In obese subjects, ASP decreased with loss of weight (Muscari et al., 1990) and post 
obese women with normal weight had normal ASP levels (Faraj et al., 2001).  
Plasma C3 also decreased with loss of weight (Pomeroy et al., 1997, Pasquali et al., 
1987, Fisler et al., 1982) and in anorexia nervosa (Pomeroy et al., 1997).  Factor B 
and factor D (adipsin) have been found to be decreased with weight loss (Pomeroy et 
al., 1997, Mavri et al., 1999) and in anorexia nervosa (Napolitano et al., 1994, 
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Pomeroy et al., 1997) and improved to normal levels with weight gain in those 
subjects.   
Despite the evidence that the adipsin-ASP pathway could contribute to increasing 
fetal fat mass (Saleh et al., 2008) neither adipsin and ASP function nor their levels in 
mothers and developing fetus have been investigated in the context of obese 
pregnancy and GDM pregnancy. 
 
1.28 Leptin 
1.28.1 Identification of Leptin 
Leptin was the first adipocyte hormone identified which has a direct consequence on 
the hypothalamus and influences food intake (Halaas et al., 1995, Lee et al., 1996).  
Leptin is cytokine of 16-kDa peptide, which is produced by adipose tissue and a 
circulating factor performing both peripherally and centrally, whose effects are 
mediated through its OB-Rb receptor, also regulate metabolic and inflammation 
functions (Tartaglia et al., 1995).  Leptin, meaning thin from the Greek leptos, is a 
product of the cytokine obese gene (ob), which is produced by both white and brown 
adipocytes.   It is a pleiotropic protein that belongs to the cytokine family with long- 
helical chain which has similar structure with interleukins like IL-6, Il-12, Il-15, 
granulocyte colony stimulating factor and oncostatin M.  Leptin has an extensive 
variety of biological actions including regulation of hypothalamic-pituitary-adrenal 
axis, reproduction, metabolism of glucose and insulin, lipolysis, immune and 
inflammatory response, sympathetic nerve activity, hematopoiesis, angiogenesis, 
blood pressure, bone formation and wound healing (Ahima and Flier, 2000, 
Friedman, 1998, Fruhbeck and Gomez-Ambrosi, 2001, Otero et al., 2005, Frank et 
al., 2000, Murad et al., 2003).   
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1.28.2 Role of leptin 
Leptin concentrations in plasma are extremely linked with body mass index (BMI) 
both in rodents and humans (Maffei et al., 1995).    An obese phenotype has been 
induced by mutation of leptin receptor in mice (db/db) and in rats (fa/fa) (Frederich 
et al., 1995, White and Martin, 1997).  Leptin is found to control appetite as well as 
energy outflow through hypothalamic pathways and it is produced in equivalent to 
the body adiposity (Friedman and Halaas, 1998).  Leptin is known to be a modulator 
of various inflammatory and immune responses along its metabolic and endocrine 
functions (Juge-Aubry and Meier, 2002, Fantuzzi and Faggioni, 2000).  Leptin 
inhibits the immune response also; food deprivation decrease leptinaemia and 
lymphoid tissue are atrophied in both humans and rodents (Chandra, 1991, Ahima et 
al., 1996).  Furthermore, the serum level of leptin and the leukocyte count were 
strongly correlated (Juge-Aubry and Meier, 2002).   
 
1.28.3 Role of Leptin in Obesity 
Leptin stimulate the process of lipolysis through direct effects on both adipose tissue 
and on pancreatic cells (Siegrist-Kaiser et al., 1997, Maedler et al., 2004, Seufert, 
2004).  It has identified that the lack of gene coding for leptin in mice (ob/ob) are 
found to be very obese and diabetic (Halaas et al., 1995).  When treated with leptin 
injections in ob/ob mice, they reduce their food intakes which in turn increase their 
metabolic rate and results in loss of weight (Halaas et al., 1995, Pelleymounter et al., 
1995).  Genetic mutation in both mice and rats, which affects the receptor of leptin in 
the hypothalamus, reveals the same phenotype to ob/ob mice (Lee et al., 1996, Chua 
et al., 1996).   
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The function of leptin in regulating the body weight has converted to more 
multifaceted in both animals and humans who become obese.  There are a few cases 
where a mutation, which affects the gene coding for the leptin receptor, has been 
found with a high incidence of morbid obesity (Montague et al., 1997, Farooqi et al., 
2001, Clement et al., 1998).  However, leptin therapy has an effect in children with 
leptin deficiency (Farooqi et al., 2002, Farooqi et al., 1999).   
The leptin concentrations are very high due to increased levels of leptin secreting 
adipose tissue in obese individuals (Farooqi et al., 1999). However, with increase in 
leptin concentrations, this in turn triggers the objective cells to become resistant.  The 
effect of leptin in the mouse with congenital lipodystrophy on peripheral metabolism 
resulting in insulin resistance, hyperglycemia, hyperinsulinemia and enlarged fatty 
liver and therapy with leptin upturned  insulin resistance and diabetes (Shimomura et 
al., 1999).  In lipotrophic diabetes disorder (little or no fat mass) in humans, there is 
reduced leptin in serum and increases in serum triacylglycerol concentrations.  This 
leads to an inflamed fatty liver, which results in severe liver disease.  Thus, leptin is 
an important hormone acts on energy balance and metabolism on both central and 
peripheral effects.   
Leptin leads to a considerable reduction of fat mass, has an effective role on lipid 
metabolism within several days of administration (Pelleymounter et al., 1995).  
Leptin increases glucose metabolism in spite of its reducing action in bodyweight, 
proving its range of activity is not only on lipid metabolism and besides on glucose 
metabolism (Kamohara et al., 1997).   
 
1.28.4 Role of Leptin in Obese and GDM Pregnancy 
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Several studies have discussed the leptin’s role in reproductive function.  The 
significance of sufficient nutrition, for the maintenance of reproductive function has 
also been well studied.  However, inadequate nutrition delays which  prevents the  
puberty onset but relating  nutrition to the reproductive system has not been fully 
studied (Aubert and Sizonenko, 1996).  Severe lipodystrophy is distinguished by low 
leptin levels, caused by destruction of adipose tissues (Oral et al., 2002).  Other 
abnormalities include hypertriglyceridemia and severe insulin resistance which is 
generally associated with diabetes mellitus (Van Gaal et al., 2003).  There are several 
studies on genetically engineered animal models as well as in humans in several 
genetic and acquired forms of lipodystrophy has demonstrated the metabolic 
abnormalities as a result of loss of fat (Gavrilova et al., 2000, Savage and O'Rahilly, 
2002).  Leptin has a definite role in preventing the insulin resistance, and 
hypertriglyceridemia of lipodystrophy.  Of interest,  replacement therapy with leptin 
reaches the physiological levels to a remarkable enhancement in insulin resistance, 
hyperglycemia, hypertriglyceridemia and hepatic steatosis in a mouse model of 
lipodystrophy (Shimomura et al., 1999).  Hyperleptinemia corrects steatosis in 
diverse organs that act as sites of lipid accumulation, such as liver, islet cells and 
heart in diet-induced obesity (Lee et al., 2001).   
Leptin plays an important role in transmitting signals for energy status to the central 
nervous system and it crosses the blood-brain barrier (BBB) to act on the arcuate 
nucleus (Banks and Farrell, 2003).  Failure of the leptin transporter is considered as a 
key supplier to the development of leptin resistance in obesity.  The BBB transporter 
for leptin is mediated by epinephrine, insulin, glucose and triglycerides and by 
starvation too (Banks, 2004). 
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 Leptin is directly correlated with obesity (Havel, 2002).  Leptin resistance has been 
replicated  by hyperleptinemia is considered to associate obesity to impaired glucose 
metabolism, hypertension and pro-atherogenic status (Correia and Rahmouni, 2006).  
Leptin signaling is also liable for modulation of food intake and expenditure of 
energy (Correia and Rahmouni, 2006, Havel, 2002).  Pregnancies complicated by 
GDM are associated with hyperleptinaemia (Kautzky-Willer et al., 2001).  Insulin 
influences leptin expression on glucose metabolism (Wellhoener et al., 2000).  
Leptin also mimics some of insulin’s actions in the adipose tissue, liver and muscle 
(Berti et al., 1997, Berti and Gammeltoft, 1999). 
 
1.29 Non Esterified Fatty Acids (NEFA) 
The metabolism in normal pregnancy is distinguished by low normal glycaemia and 
physiological hyperlipidemia (Herrera, 2000, Nolan et al., 1995).  Pregnant women 
with higher levels of non-esterified fatty acids (NEFA) in the third trimester are more 
possible to be obese or overweight (Chen and Scholl, 2008).  Obese women in 
pregnancy also have abnormal lipid proteins (Ramsay et al., 2002).  However, type 2 
DM, gestational diabetes and poorly controlled type 1 diabetes are regularly related 
with higher levels of plasma lipids than in normal pregnancy (Nolan et al., 1995, 
(Koukkou et al., 1996, Hollingsworth and Grundy, 1982).  Increased NEFA levels 
have been shown to be associated with intrauterine growth retardation (IUGR), 
preterm delivery (Chen and Scholl, 2008), preeclampsia with IUGR (Alvino et al., 
2008) and fetal adiposity (Schaefer-Graf et al., 2008). In fetal growth, the role of 
maternal hyperlipidemia is not yet clearly defined as maternal triglycerides do not 
cross the placenta and transfer of fatty acids, even though stimulated during late 
gestation, is very poor compared to glucose diffusion across the placenta 
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(Magnusson et al., 2004).  The transport of fatty acid into the fetal environment 
would be essential for the establishment of endogenous factors to increase trapping 
of fatty acid and fat storage which is enhanced during late gestation (Magnusson et 
al., 2004).  During early gestation, the fat content in fetal compartment increases 
about 0.5% of body weight to 16% at term which increases in fetal birth weight.  
This increase in birth weight is due to fatty acids transfer  from the mother to the 
fetus as maternal lipid levels in serum, which increases the lipogenesis during late 
gestation (Saleh et al., 2007).  Magnusson-Olsson et al (Magnusson-Olsson et al., 
2006) has reported that fatty acids crosses the placenta from lipolysis of maternal 
triglycerides by lipoprotein lipase found to be dynamic in the placenta at late 
gestation. However, the mechanisms regulating this are not completely understood. 
 
1.30 Fibroblast Growth Factor 21-FGF21 
 Fibroblast growth factor  (FGF family)  has 22 members which have a extensive 
variety of biological effects (Ornitz and Itoh, 2001) including regulation of cell 
growth and differentiation (Gospodarowicz, 1974).  FGF polypeptides were named 
initially by their ability to stimulate the proliferation of fibroblast.   Among FGF 
family, FGF19, FGF21 and FGF23, which are all members belonging to the same 
FGF subfamily, have significant metabolic functions (Beenken and Mohammadi, 
2009). Fibroblast growth factor 21 is a novel member of FGF family.  FGF21 is 
principally produced by liver and adipose tissues (Badman et al., 2009), and plays a 
significant role in control of glucose metabolism and energy balance (Badman et al., 
2009).   In contrast, FGF19 is produced in the intestinal epithelium, which has been 
found to regulate the synthesis of cholesterol and bile acid (Inagaki et al., 2005).  
FGF23, in contrast, is predominately produced in the bone and regulates absorption 
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of phosphate and biosynthesis of vitamin D through the kidneys (2000).  However, 
an exact knowledge of bioactivity of FGF21 and its mode of action have been 
missing to date.   
Recently, FGF21 has been found to regulate metabolism and as a hormonal mediator 
of adaptive starvation.    FGF21 was found to reduce the concentration of glucose 
and triglyceride in the plasma of  db/db and ob/ob mice and activates uptake of 
glucose in adipocytes, in turn protecting against diet induced obesity in transgenic 
mice; moreover, FGF21 improves lipoprotein when administered to diabetic rhesus 
monkeys (Kharitonenkov et al., 2005, Kharitonenkov et al., 2007, Wente et al., 
2006).   FGF21 has been found to be a novel pharmacological target for the obesity 
treatment and other related metabolic disorders (Kliewer and Mangelsdorf, 2010).   
FGF21 treatment in obese rodents has been found to reduce body fat content and 
improve glucose tolerance, insulin sensitivity and hepatic and circulating lipid 
parameters (Coskun et al., 2008, Xu et al., 2009, Berglund et al., 2009).  FGF21 
mediated weight loss has been found to be involved in an increase in fat oxidation 
and metabolic rate with no change of intake of food (Coskun et al., 2008). 
Interestingly, the insulin-sensitizing effects of FGF21 are reliant on reduced body fat 
and largely attribute to improved insulin action in the liver (Potthoff et al., 2009).  
This proposed that FGF21 might regulate hepatic substrate metabolism through a 
mechanism on hepatocytes that cannot be enlighten by a direct effect (Potthoff et al., 
2009).  FGF21 levels are positively associated with metabolic syndrome,  obesity 
and type 2 DM (Kharitonenkov et al., 2005,(Zhang et al., 2008, Li et al., 2008, Lin et 
al., 2011).  The hypothalamus has an abundance of neuropeptides that regulate 
satiety (Enriori et al., 2007). Of note, these neuropeptides, such as NPY, orexin, 
CRH are also present in adipose tissue. Interestingly, on the flip side,  Hsuchou et al 
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(Hsuchou et al., 2007) has shown, in mice, that FGF21(an adipokine and hepatokine)  
crosses the blood-brain barrier (BBB) and hence that FGF21 from peripheral could 
reach the brain directly and coordinate its central effects (Hsuchou et al., 2007, 
Sarruf et al., 2010).   
Recently, Tan et al (Tan et al., 2011) investigated whether this observation extended 
to humans. They sought to determine the FGF21 existence in human cerebrospinal 
fluid (CSF) and its relation to metabolic parameters. They established significantly 
elevated circulating FGF21 levels in CSF in obese compared with lean subjects, and 
that fat mass was the only influential factor of both circulating and CSF FGF21 
levels. However, there were negative correlations between the CSF to plasma FGF21 
ratio and BMI and fat mass, and the authors suggest the competence of FGF21 
uptake into the CSF is reduced in obese subjects.  
 
1.31 The Placenta  
The placenta can produce and also respond to multiplicity of inflammatory stimuli. 
The placental resident macrophages (Hofbauer cells), syncytiotrophoblast and 
cytotrophoblast cells produces the cytokines.   Nevertheless, the accurate physiologic 
role of placental cytokines, with progression of pregnancy, is still indistinct.   
 
1.31.1 Placental Macrophages 
Macrophages are the main cell type in the uteroplacental unit and are particularly 
profuse in the fibrous tissues of the placenta and in the decidua (Bulmer and Johnson, 
1984, Lessin et al., 1988).  Macrophages are found clustered near the implantation 
site in rodents (Tachi et al., 1981).  Macrophages are forbidden from colonizing the 
decidua basalis as pregnancy progresses and are dispersed throughout the 
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myometrium and stroma of endometrium of mice (Redline et al., 1988) and in rats 
(Hunt et al., 1989).  Macrophages has been identified by the isolation of placental 
cells in human tissues (Moskalewski et al., 1975) and in the mesenchymal stroma of 
the placenta (Wood et al., 1978, Wood and King, 1982).  Fetal macrophages 
accumulate in the mesenchymal stroma between the extraplacental membranes, 
amnion and chorion (Bulmer and Johnson, 1984, Lessin et al., 1988) and in the yolk 
sac membranes (Wood, 1980).   
The placental villus in human is composed of syncytiotrophoblast, the superficial cell 
layer lining the intervillous space, which is in direct contact with the maternal 
circulation and adjacent to fetal capillaries, as well as stromal cells which consists of 
fibroblast and Hofbauer cells (Castellucci et al., 2000, Georgiades et al., 2002).  
More than 100 years ago, Hofbauer cells (HBCs) were identified in the placental 
villus.  Hofbauer cells were found to be large pleomorphic cells of about 10-30 µm 
and highly vacuolated with a granular cytoplasm (Georgiades et al., 2002, 
Castellucci et al., 2000).   
Hofbauer cells are first visible on the 18
th
 day of gestational period and found until 
term gestation (Castellucci et al., 1980).  In the mid trimester, the placental villous 
stroma makes their identification difficult due to compression; this has provoked the 
use of antibodies raised against macrophage proteins like CD68 and CD163 using 
immunocytochemistry (Fox, 1967, Kim et al., 2008).  Several researchers have 
identified Hofbauer cells might play a role in early placental development by 
influencing vasculogenesis (Seval et al., 2007), angiogenesis (Khan et al., 2000), and 
mesenchymal maturation (Ingman et al., 2010).   
Placenta and the obesity have been less researched.  Obesity is linked with larger 
placental size and accumulation of placental macrophages and inflammation 
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(Challier et al., 2008).  In GDM and type 1 DM, placentae were shown to have 
altered genes in lipid metabolism in placenta (Radaelli et al., 2009).  There is only 
limited information about fatty acid metabolism in pregnancies of obese women and 
gestational diabetes in human placenta (Szabo and Szabo, 1974, Lindegaard et al., 
2006). 
 
1.31.2 Placental Cytokines 
The cell types identified almost in the uteroplacental tissues contribute in the 
production of cytokines (Hunt, 1989).  Human placenta has been shown to express 
more cytokines.  However, their chronological prototype of expression is still 
moderately understood (Bowen et al., 2002).  The placental resident macrophages 
(Hofbauer cells), syncytiotrophoblast and cytotrophoblast cells produces the 
cytokines.  All these three cell types allocate similarities with respect to the receptor 
expression, the ligand production and in their mechanism of action  (Guilbert et al., 
1993).  
Most of the cytokines produced by the placenta are similar to that secreted by 
adipose tissues.  During the third trimester, these might contribute to the low grade 
systemic inflammation (Lepercq et al., 1998, Kirwan et al., 2002, Radaelli et al., 
2003).   The reported cytokines in placenta are TNF α, leptin, and IL-6 (Guilbert et 
al., 1993, Lepercq et al., 2001, Malek et al., 2001), though their role is not 
understandable.  Accordingly it may be significance in studying the placental 
cytokines in the third trimester. 
The production of TNF-α by the Hofbauer and the trophoblast cells (Chen et al., 
1991, Phillips et al., 2001) has not been estimated. On the contrary, 
syncytiotrophoblast cells are the main sites of synthesis of leptin and   IL-6 (Phillips 
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et al., 2001).  There is much facts that the combination of placental and T cell 
derived cytokines is involved
 
in pregnancy (Kirwan et al., 2002).  
The physiological role of placental cytokines in pregnancy becomes uncertain.   One 
established hypothesis is that numerous placental cytokines released into the 
maternal systemic circulation contribute to metabolic changes to regulate increased 
energy needs of the fetus during the third trimester of pregnancy (Lepercq et al., 
2001, Kirwan et al., 2002, Malek et al., 2001). 
Due to increased local production of cytokine release into the maternal circulation is 
related with gestational complications like diabetes and pre-eclampsia (Lepercq et 
al., 1998, Benyo et al., 2001, Coughlan et al., 2001).  As a result of increased release 
of cytokine might lead to the activation of particular inflammatory pathways, in turn 
induces maternal insulin resistance, which is necessary for the normal gestational 
sequence (Redman and Sargent, 2003, Radaelli et al., 2003). 
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Thesis Aims 
Pregnancy which demands significant nutritional requirements on the mother and 
placenta have found to release cytokines and more recently some adipokines.  While 
it is now established that increased maternal adiposity directly affects the physiology 
of the developing fetus, the mechanisms by which these processes occur are 
incompletely understood.  However, comparatively little work has been performed in 
humans examining the role of adipose tissue derived factors in obese and GDM 
pregnancies.   
With the aforementioned in mind, this thesis has hypothesized that alterations in 
adipose tissue derived factors such as adipsin and its downstream effector Acylation 
stimulating Protein (ASP) might underpin an altered nutritional state in pregnancy.  
Adipsin/ASP might represent a mechanism by which the weight gain in the fetus of 
obese mothers might be explained. 
Therefore, this thesis aims to investigate and establish the following points: 
 
Aim-1 
Can the generation of a well characterized cohort of patients allow the 
dissection of molecular mechanisms of adipsin/ASP action? 
Many studies have failed to determine important differences because of variation in 
clinical samples.  Hence I focused on patients undergoing cesarean section because 
a) they are all delivered at the same gestation (39 weeks), b) they are all fasted 
(permitting meaningful interpretation of parameters such as HOMA-IR and c) access 
to tissues (adipose, placenta) is more straight forward. 
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Aim- 2 
Do circulating concentrations of adipsin and ASP in both fetal and maternal 
establish a marked difference in obese pregnancies as well in diabetic 
pregnancies compared to lean pregnancies? 
Adipsin and ASP are well known to play significant roles in triglyceride storage and 
are increased in circulating levels in obesity.  The Adipsin levels in human 
pregnancy, an insulin resistant state, have not previously been studied, but the ASP 
levels have been described, with the evidence of increased maternal ASP at late 
gestation and increased fetal ASP in conjunction with the elevated maternal 
triglycerides.  The lipid transfers are regulated in the normal placenta from maternal 
to fetal blood through storage and release of FFA, which is essential for energy 
source for the growing embryo.  However, no previous reports have examined 
adipsin and ASP in both obese pregnancy and diabetic pregnancy. Therefore this 
thesis aims to investigate the circulating concentrations of maternal and fetal adipsin 
and ASP in lean, obese and GDM pregnancies and their corresponding cord bloods. 
 
Aim-3 
Does the placenta release Adipsin and ASP? 
Increased fetal concentrations of adipsin and ASP in both obese and GDM pregnancy 
were observed. This has speculated whether the placenta might be a source of these 
molecules.  Moreover, a very important thrust has aimed to investigate the release of 
adipsin and ASP from placenta and adipose tissue. 
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Aim-4 
 Where is the localization of adipsin and ASP in the placental tissues? 
 
The secretion of both adipsin and ASP in the placenta has been identified, for the 
first time.  This novel identification has intended to discover the cell types within the 
placenta that were responsible for the synthesis and secretion of these molecules.   
 
Aim-5 
Are there any differences in protein binding of FGF21 in lean, obese and GDM  
 
Pregnancies ? 
 
Having described FGF21, as a regulator of metabolism and were positively 
associated with obesity and type 2 DM and has been reported to be produced in the 
brain.  Therefore this work was aimed further to investigate the FGF21concentrations 
in CSF corresponding to plasma levels within these cohorts (lean, obese and GDM 
pregnant) to describe the differences. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
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2.1 SUBJECTS AND ETHICS 
All study participants were pregnant women scheduled for elective caesarean section 
delivering at 39-40 weeks of gestation, and was identified from the operating theatre 
lists generated in the University Hospitals Coventry & Warwickshire Maternity 
department.  The study protocol was approved by The Coventry Local Research 
Ethics Committee for Human Experimentation of the Medical University of 
Warwick (Research Ethics Committees 07/H1210/141).   All the study participants 
filled out written informed consent forms. 
After the evaluation of body weight and height, the body mass index (BMI) was 
determined using the formula-BMI=body mass in kilograms/height in square meters.   
Accordingly, the study participants were divided into 3 groups:  
1. Control group - group of thirty-five pregnant lean women in whom pre-pregnancy 
body mass index was determined within the range of 18.9-24.9 (lean pregnant-BMI 
19-25, mean age 32 years; range 18-44),  
2. Test group 1 (Obese) - group of thirty-nine obese pregnant women, in whom pre-
gravid body mass index was determined above 30.0 (obese pregnant-BMI>30, mean 
age 32.49 years; range 22-44) and 
3. Test group 2 (GDM) – group of eighteen pregnant women with gestational 
diabetes in whom pre-pregnancy body mass index was determined above 30.0 
(GDM-BMI-31.16; range 23-46, mean age 34.4 years; range 26-47) were recruited. 
All the patients filled in a questionnaire which consisted of questions concerning 
maternal age, gestational age, parity, pre pregnancy weight, height, obstetric history, 
previous caesarean sections, illnesses, smoking, alcohol consumption and indications 
for the caesarean section. Subjects with multiple pregnancies, cardiovascular 
diseases, preeclampsia and other metabolic disorders were excluded from the study.   
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Oral glucose tolerance tests (OGTTs) at 26-28 weeks gestation in pregnancy or in the 
preceding 6 months for non-pregnant controls had been performed in all participants 
to characterize glucose metabolism and exclude diabetes.       
 
2.2 ANALYSIS 
Paired maternal venous and cord blood samples were collected at the time of 
caesarean section and were centrifuged (spun at 3000g-Beckman Coulter DS-9623C) 
immediately.    The supernatant were collected (serum and plasma) and stored 
immediately at -80˚C until analysis.  Cerebrospinal fluid (CSF) was also collected 
during spinal anaesthesia and immediately frozen in liquid nitrogen and preserved at 
-80˚C until analysis.  Venous blood samples were collected in plain tubes without 
anticoagulant for glucose, insulin and the measurements of lipid profile and EDTA 
tubes for Adipsin and ASP measurements.  All samples were analysed for the fasting 
glucose, lipid profile, including TGs, total cholesterol, high-density lipoprotein 
cholesterol (HDL) and low -density lipoprotein cholesterol (LDL).   Plasma glucose 
levels quantification and lipid profile analysis were performed using an automated 
clinical chemistry analyzer Roche modular system (Roche Diagnostics Scandinavian, 
Bromma, Sweden).  The score of insulin resistance by Homeostasis Model 
Assessment (HOMA-IR) was calculated as previously described (Matthews et al., 
1985).  All other chemicals and reagents were from Sigma-Aldrich (Gillingham, UK) 
unless otherwise stated. 
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2.3 HUMAN INSULIN ELISA 
The technique was performed according to the protocol of manufacturer (Invitrogen, 
Camarillo, CA, USA).   It is an immunoenzymatic assay for the quantitative 
measurement of human insulin in human serum.  Briefly, 50µL of standards, controls 
and serum samples were added to antibody coated micro well plate, simultaneously 
50µL of anti-Insulin-HRP conjugate were added into all wells, and incubated for 30 
minutes at room temperature with continuous shaking.   Following this, the wells 
were aspirated and washed 3 times with wash solution. After the wash, 100 µL of 
stabilized chromogen was added within 15 min of washing and incubated in the dark 
for 15 minutes at room temperature.  Finally, 100 µL of stop solution was added and 
absorbance was recorded at 450 nm using an ELISA plate reader (EL800, Bio-Tek 
Instruments, Inc., Winooski, VT, USA).  The minimum detection limit for the assay 
is 0.17µIU/ml.   Graph pad prism4 and Graph pad Instat (www.graphpad.com) were 
used to generate the standard curve. The concentrations for unknown samples and 
controls from the standard curve were determined from this curve. 
 
2.4 HUMAN ADIPSIN ELISA 
This protocol was performed according to the manufacturer’s instructions 
(Adipobioscience, Cambridge, UK).   Briefly, all the working standards and reagents 
were prepared and plasma samples were diluted (1:4000).  Then 100 µL of standard, 
samples, positive controls were added to antibody coated micro-well plate and 
incubated for 2 hours on the plate shaker at room temperature.   Followed this, the 
wells were washed for 4 times with wash solution.   Then 100 µL of Detection 
Antibody was added to each well and then incubated for 2 hours on the plate shaker 
at room temperature followed by wash for 4 times.   Then 100 µL of Streptavidin 
59 
 
HRP conjugate was added to each well and incubated  for 45 minutes on the plate 
shaker at room temperature followed by wash for 4 times. 100 µL of Substrate was 
added to each well and incubated for 5-10 minutes in the dark.   Then 100 µL of Stop 
Solution was added to each well.  The absorbance was recorded at 450 nm (reference 
wavelength at 540nm) using an ELISA plate reader (EL800, Bio-Tek Instruments, 
Inc., Winooski, VT, USA).  The minimum detection limit for the assay is 15.6 pg 
/ml.  Graph pad prism4 and Graph pad Instat was used to generate the standard 
curve.   The concentrations for unknown samples and controls from the standard 
curve were determined from this curve. 
 
2.5 TISSUE EXPLANT CULTURE 
Paired explants experiments were performed by using placentae and subcutaneous 
adipose tissue from lean (n=4), obese (n=4) and GDM pregnant patients (n=4) 
undergoing elective caesarean section at term.  Paired placental and subcutaneous 
explants from lean, obese and GDM pregnant patients were prepared as previously 
described (Gould et al., 2010, Tan et al., 2007).   The procedures were done under 
sterile condition.   The fresh tissues of placenta and subcutaneous fat were collected 
in PBS, and  samples were washed in PBS for 4 times.  Areas of each placenta were 
randomly sampled and villous tissue was cultured on Costar Net well plates 
(Corning, NY). Adipose tissue explants (identical tissue weight for lean, obese and 
GDM pregnant) were cultured in 6-well plate.  Briefly, to make up-to 1 litre of 
medium, 100mls of Fetal Calf Serum (GIBCO 10108-157) was incubated in 37ºC to 
thaw.  Then 100ml of CMRL-1066 (GIBCO 21540 10x concentrate) culture medium 
concentrate was added to 800ml of MilliQ water and 2.2g NaHCO3 was added. 
Following this, 100mg streptomycin sulphate (SIGMA S-1277), 60mg penicillin 
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G(SIGMA penicillin G 1,000,000 units P-3032), 100µg hydrocortisone (water 
soluble hydrocortisone SIGMA H-0396), 1mg of Insulin (SIGMA I-6634), 100µg 
retinol acetate (SIGMA R-0635;retinol acetate water soluble), 100mg of L-glutamine 
were added.   Then pH of the culture medium was adjusted to 7.2 by adding a few 
drops of 10 M NaOH.   About 800ml of MilliQ water was taken in 1 litre beaker and 
the prepared medium was added and then filtered through a 0.22µm filter. 
1.5ml of prepared culture medium to each well was used in all sterile culture plates 
(net well plates were used for placental tissue) and placental as well as adipose 
explants were cultured in the medium.  Both the explants were treated without and 
with insulin (2.5 µl or 0.00875 mg of insulin to 1.5 ml of medium to each well).   The 
plates were incubated in the incubator for 2 days under 5% CO2 and 95% air.  Media 
aliquots were collected after 24 hours and 48 hours of incubation, centrifuged at 
1000 rpm (46g) for 5 min and supernatants were stored in –80ºC until assayed.   
Simultaneously, the tissue explants were then weighed and stored in –80ºC. 
 
2.6 IMMUNO-CYTOCHEMISTRY STAINING 
The technique was performed using ImmPress Universal Reagent, Anti-Mouse/rabbit 
IgG (Vector Laboratories, Inc., Peterborough, UK).  It is based on a new staining 
method of polymerization of enzymes and attaching these polymers to antibodies.  
About 8 µm frozen placental sections were obtained using a cryostat (Leica 
Microsystems, Milton Keynes, UK) and air dried.  Immuno histochemistry analyses 
were performed on serial sections of placenta as described previously (Gould et al., 
2010). Immediately before staining, sections were fixed with 75% ethanol for 5 min 
and the slides were transferred into water.  Then 2.5 ml of 0.3% H2 O2 in 22.5ml of 
methanol were added to the sections to lessen the risk of antigen destruction or tissue 
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loss and also for quenching of endogenous peroxidise for 30 minutes, followed by 3 
washes in water for 5 minutes. The sections were incubated for 30 minutes with 
2.5% normal horse blocking serum.   Following this, the sections were incubated 
with mouse antihuman adipsin antibody (Santa Cruz Biotechnology, Inc., UK) 
diluted (1:100) in appropriate diluents solution (PBS) for 1 hour. The slides were 
then washed in water for 3 times for 5 minutes.   Subsequently, the slides were 
incubated with Immpress reagent for 30 minutes and washed 3 times in water for 5 
minutes.   After this, the sections were incubated in peroxidase substrate solution for 
5 minutes until the desired stain intensity was developed. Haematoxylin was added to 
the sections for 1 minute and washed with PBS.   Then it was rinsed in75% ethanol 
for about 1 minute.   Following this, the sections were immersed in 100% ethanol 
and Xylene.   The slides were then counterstained, cleared and mounted and adipsin 
positive cells were detected. 
 
2.7 HUMAN EIA ASP (C3adesArg) DETERMINATION 
This protocol was performed according to the manufacturer’s protocol (ENZO life 
sciences, Exeter, UK).  This EIA human complement C3adesArg kit is a competitive 
immunoassay for the quantitative determination of C3adesArg in plasma.  All plasma 
samples were treated with the reagents provided to precipitate whole protein from 
plasma, as whole protein in the sample competes with the complement in the assay. 
About 112.5µl volumes of plasma was added to 112.5µl of complement reagent A 
and vortex thoroughly.   Then 25µl of 10.0 N Hcl was added to it, vortexed and 
incubated at room temperature for 1 hour.   Assay buffer 10 was prepared, by 
diluting 10ml of 1x of supplied concentrate with 90ml deionised water.   Then the 
samples were spun at 10, 000 rpm in a microcentrifuge for 5 minutes at room 
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temperature. 90 µl of the supernatant was transferred to a clean tube.   To this 
supernatant, 10µl of 9.0 N NaOH was added and vortexed.   Then 300µl of 
complement reagent B was added to the supernatant and vortexed thoroughly.   Then 
5.35 µl of Assay Buffer 10 was added to the supernatant and vortexed.   Then 50 µl 
of this sample was diluted with 950 µl of assay buffer 10.  Thus 1:200 dilutions of all 
plasma samples were prepared.  
In NSB and Bo wells, about 100 µl of Assay Buffer 10 was pipetted.   Then 100 µl of 
standards and 1:200 diluted samples were pipetted into the wells.   Then 50 µl of 
assay buffer 10 was added into the NSB wells. 50 µl of antibody were added into 
each wells, expect total activity and blank wells.  Then the plate was incubated at 
room temperature on a plate shaker at 500rpm for 2 hours. The plate was washed 
with the wash buffer for 3 washes.   After the final wash, 5 µl of the 1:10 dilution of 
conjugate was added to total activity wells. 200 µl of the p-Npp substrate solution 
was added to every well.   At the end of the assay, 50 µl of stop solution was added, 
which stopped the reaction and the plate was read immediately on a plate reader at 
optical density 405nm. 
This kit uses a polyclonal antibody to human C3a des Arg to bind in a competitive 
manner. The intensity of the bound yellow colour is inversely proportional to the 
concentration of C3a des Arg in either standards or samples.  The measured optical 
density was used to calculate the concentration of human C3a des Arg.  The 
minimum detection limit for the assay is 0.120ng/ml.  Graph pad prism4 and Graph 
pad Instat was used to generate the standard curve.   The concentrations for unknown 
samples and controls from the standard curve were determined from this curve   
Intra-assay coefficient of variation for this EIA was 8.7% and inter-assay coefficient 
of variation was 5.7%. 
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2.8 HUMAN LEPTIN IMMUNOASSAY 
This protocol was performed according to the manufacturer’s instructions 
(Quantikine, R&D Systems, Inc. Abingdon, UK).  Briefly, all the working standards 
and reagents were prepared and the plasma samples were diluted (1:100).  Then 
about 100 µl of Assay Diluents RD1-19 to each well were added.  About100 µl of 
standard, control and samples were added to each well and incubated for 2 hours at 
room temperature, after which each well were aspirated and washed, this process 
were repeated for three times for a total of four washes with wash buffer (400 µl).  
Then 200 µl of Leptin Conjugate was added to each well and incubated for 1 hour at 
room temperature.   The plate was then washed for four washes with wash buffer.   
Then 200 µl of substrate solution was added to each well and incubated for 30 
minutes at room temperature and protected from light.   Finally, 50 µl of stop 
solution was added to each well.   The colour in the wells changed from blue to 
yellow. The optical density of each well was determined using a micro plate reader 
set to 450nm with wavelength correction of 540 nm or 570 nm.   The minimum 
detectable dose (MDD) of Leptin for the assay is less than7.8 pg/ml.   Graph pad 
prism4 and Graph pad Instat was used to generate the standard curve. The 
concentration for unknown samples and controls from the standard curve was 
determined from this curve.   Intra-assay coefficient of variation for this EIA was 
3.2% and inter-assay coefficient of variation was 5.4%. 
 
2.9 NON ESTERIFIED FREE FATTY ACID QUANTIFICATION 
This protocol was performed using Bio vision’s free Fatty Acid quantification kit 
(Bio Vision Research Products, USA).   It is a sensitive enzyme based method for 
detecting long-chain free fatty acids in plasma.   The protocol was assayed in 100 µl 
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per micro plate well. For the colorimetric assay, 0, 2, 4, 6, 8, 10 µl palmitic acid 
standards was added into 96 well plates individually. Assay buffer was added and the 
volume was adjusted to 50 µl/well to generate 0, 2, 4, 6, 8, 10 nmol/well of the fatty 
acid standard.   Then 30 µl of samples was diluted with 20 µl of assay buffer, to 
bring up the volume to 50µl/well.  Then 2 µl of Acyl-CoA Reagent was added into 
all standard and sample wells, mixed well and incubated at room temperature for 30 
minutes.  Then a total 50 µl reaction mix was prepared containing 44 µl Assay 
Buffer, 2 µl fatty acid probe, 2 µl enzyme mix and 2 µl enhancer for each well. 50 µl 
of the reaction mix was added to each well and incubated for 30 minutes at room 
temperature and protected from light. The optical density was determined at 570 nm 
for colorimetric assay in a micro plate reader.   NEFA concentration was measured 
using graph pad prism and InStat software.  The minimum detection limit of the 
assay using this method is 2µm free fatty acid. 
 
2.9 HUMAN FGF-21 IMMUNOASSAY 
This protocol was performed according to the manufacturer’s instructions 
(Biovendor Research and Diagnostic products, Karasek, Czech Republic).   Briefly, 
100 µl of standards, reconstituted Quality controls and diluted samples (125 µl of 
sample +125 µl of dilution buffer for duplicates) were pipetted into the appropriate 
wells and the plate was incubated at room temperature for 1 hour, shaking at 300 rpm 
on an orbital micro plate shaker. The wells were washed with wash solution, 0.35 ml 
per well 3 times.   After the final wash, the plate was inverted and tapped against 
paper towel.   Then 100 µl of Biotin labelled Antibody was pipette into each well and 
the plate was incubated at room temperature for 1 hour, shaking at 300 rpm on an 
orbital micro plate shaker. After this, the wells were washed with wash solution 3 
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times.   Then 100 µl of Streptavidin –HRP Conjugate was pipetted into each well and 
incubated at room temperature for 30 minutes, shaking at 300 rpm on an orbital 
micro plate shaker. The wells were washed 3 times with wash solution.   After the 
wash, 100 µl of Substrate solution was added to each well and the micro-titer plate 
was protected from direct sunlight and the plate was incubated for 15 minutes at 
room temperature without shaking.   The colour development was stopped by adding 
100 µl of stop solution and the absorbance of each well was determined using a 
micro-plate reader set to 450 nm, with the reference wavelength set to 630 nm.   The 
minimum limit of detectable dose (LOD) of FGF-21 was typically 7pg /ml.   Graph 
pad prism4 and Graph pad Instat was used to generate the standard curve.   The 
concentrations for unknown samples and controls from the standard curve were 
determined from this standard curve.   Intra-assay coefficient of variation for this 
EIA was 3.0% and inter-assay coefficient of variation was 3.9%. 
 
2.10 WESTERN BLOTTING 
Sample preparation 
Proteins were harvested in RIPA buffer (Sigma) with protease inhibitor cocktail 
added at 0.1% v/v (Cell Signaling, UK) and following treatment, proteins were 
centrifuged at 13,000 rpm for 3 minutes and stored at -20º C until use. 
Western blotting 
Protein samples of 20 micrograms of each sample per well were separated on a 15% 
reducing polyacrylamide gel and electro blotted onto a nitrocellulose membranes 
(Millipore, Bedford, MA, USA).    The nitrocellulose  membrane was then blocked 
with 2.5% of non-fat  milk in 1M Trizma/base, 1.54M  NaCl, 0.05% Tween 20 (Tris 
buffered solution plus Tween 20, TBST, pH 7.4) for 2 hours  at room temperature, 
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and then incubated overnight at 4 °C to TBST containing primary antibodies 
[Monoclonal mouse-antihuman adipsin antibody-Santa Cruz, UK]  (dilution 1:500) 
(Santacruz, UK)] in  the blocking buffer (2.5% non-fat milk in Tris-buffered saline).   
The immunoblots were then washed thoroughly three times with TBST 0.1% Tween 
and incubated with appropriate horseradish peroxidise-conjugated secondary anti 
mouse antibodies (1:5000) (Vector labs, UK) for one hour at room temperature.   
Membranes were washed in TBST and antigen-antibody complexes were visualized 
by chemiluminescence kit using a SuperSignal West Pico kit (Thermo Scientific 
Pierce Protein biology Products, Rockford, Illinois, USA).  Signal was quantified on 
a Chemigenius bioimaging system using the genetools program (Syngene, 
Cambridge, UK).   Then, for standardization, the same membranes were then 
stripped by submersion in stripping buffer [10% SDS (Bio-Rad Laboratories, Hemel 
Hempstead, UK), 1M Tris-HCl (Sigma-Aldrich, Gwellingham, UK), and pH 6.8, β-
mercaptoethanol (Sigma-Aldrich, Gwellingham, UK) for 30 minutes with gentle 
agitation. After washing with TBS-0.1% Tween at room temperature for 10 minutes, 
the  membrane were then blocked by incubation in 2.5% non-fat milk in 1M 
Trisma/base, 1.54M NaCl, 0.05% Tween 20 (Tris buffered solution plus Tween 20, 
TBST, pH 7.4) for about  one hour. Following this the membrane was re-probed with 
the mouse anti human β-actin antibody (Abcam Cell Signalling Technology Inc., 
USA; 1 in 5,000 dilutions). 
 
 2.11 ISOLATION OF PLACENTAL CYTOTROPHOBLAST, FIBROBLAST 
AND HOFBAUER CELLS    
Placental cells were isolated as previously described by (Tang et al., 2011b).   
Briefly, isolation of the different cell types comprising placenta was initiated through 
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protocols previously employed to obtain cytotrophoblasts (CTs) using trypsin/DNase 
I digestion and discontinuous Percoll gradient fractionation (Kliman et al., 1986).   
CTs (>95% purity) were generated following enzymatic digestion of placenta with 
trypsin, centrifugation on Percoll gradients, and negative immuno-selection by 
simultaneous incubation with anti-CD45 and anti-CD9 antibodies.  HBC were 
isolated using collagenase digestion of the trypsin-treated tissue, followed by 
centrifugation on Percoll gradients and negative immuno-selection by sequential 
incubation with anti-EGFR and then with anti-CD10 antibodies.  Cultures of FIBs 
(>95% purity) were obtained from cells attached to magnetic beads containing CD9 
and CD45 antibodies from CT isolations and those attached to anti-CD10 beads from 
HBC preparations.   HBC were isolated with 98-99% purity and a yield of 130-200 x 
10(6) cells/80-100 g of tissue. 
 
2.12 IMMUNOFLUORESCENCE  
Placental sections were obtained as described previously in immuno-histochemistry 
methods.  These were fixed for 10 minutes in 100% cold acetone at room 
temperature.   After extensive washing in PBS, the slides were incubated for 
additional 30 min at room temperature in PBS supplemented with 1% BSA.   After 
washing three times in PBS, the slides were incubated overnight with either a rabbit 
polyclonal antibody directed against rabbit anti-human adipsin (1:500) or mouse 
anti-human CD206 (1:150) for HBC or a mouse anti-human CK7 (1:100) for 
trophoblast or a mixture of the above antibodies.   After extensive rinsing with PBS, 
the slides were incubated for 1 h with either anti-mouse coupled to Alexa Fluor 488 
(1:200) or anti-rabbit coupled to Dylight Fluor 633 (1:200) or a mixture of both of 
these secondary antibodies (Thermo Scientific Pierce Protein Biology Products, 
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Rockford, Illinois, USA).    Slides were washed three times with PBS, mounted and 
examined using a Zeiss LSM-510 confocal microscope (Zeiss, Jena, Germany) (Zhu 
et al., 1994).   Acquisition parameters were kept constant and below background 
signal (as determined by samples incubated without primary antibody) to allow 
comparison between different samples.  
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RESULTS: 
 3.1 Anthropometric and biochemical characteristics: (Lean and Obese 
pregnant) 
The anthropometric and metabolic characteristics between lean pregnant and obese 
pregnant groups are presented in the Table 3.1.The characteristics of maternal age in 
years, booking BMI in kg/m
2
, mean gestational age at delivery in weeks, fasting 
status and OGTT in 26-28 wks between lean pregnant and obese pregnant are 
tabulated. The booking BMI of obese pregnant (33.723kg/m
2
) were significantly 
higher than the lean pregnant (23.477kg/m
2
). The birth-weight of obese off springs 
(3.61kg±0.03) was significantly higher than the babies of lean pregnant 
(3.51kg±0.04). The HOMA-IR values were calculated which were found to be 
elevated in obese pregnant women and their fetuses as measured in cord blood 
compared to lean pregnant women and their fetuses. 
 
 3.2 Maternal and fetal biochemical profiles (Lean and obese pregnant women) 
The maternal and fetal biochemical profiles between lean and obese are summarized 
in Table 3.2.There were no statistically differences in the glucose and HDL 
cholesterol levels between lean pregnant and obese pregnant women or their 
corresponding fetuses. However, statistically significant differences (p<0.05) were 
found in the levels of total cholesterol, triglycerides and LDL which were all 
elevated in obese pregnant mothers as well as their corresponding fetal cord bloods 
compared to the lean pregnant mothers and their fetuses. The Insulin levels were 
significantly (p=0.008) elevated in obese pregnant compared to lean pregnant 
women.  The leptin levels were significantly (p<0.0001) elevated in obese mothers as 
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well as their corresponding fetal cord bloods (p<0.0007) compared to lean pregnant 
women and their fetuses. 
 3.3 Maternal and Fetal HOMA-IR (lean and obese pregnant) 
The HOMA-IR values were calculated, which were found to be elevated in obese 
pregnant women (2.436±0.21 compared to lean pregnant women (1.64±0.283). 
Similarly, the HOMA-IR values were also elevated in the off spring of obese 
pregnant as measured in cord blood (2.171±0.288) compared to fetuses of lean 
pregnant women (1.165±0.18) (Fig.3.1) 
 
 3.4 Maternal Glucose and lipid concentration (lean and obese pregnant) 
Maternal glucose levels quantification and lipid profile analysis in serum between 
lean and obese pregnant women were performed using automated chemical analyser. 
The glucose levels (4.28mmol/l) were similar between both lean and obese pregnant 
women.  The total cholesterol of obese pregnant (6.743 mmol/l±0.194) were 
significantly higher than the lean pregnant (6.086mmol/l±0.235). Similarly, the 
triglycerides (mmol/l) of obese pregnant (2.887±0.14) were significantly higher than 
the lean pregnant (2.494±0.12). Similarly, the LDL (mmol/l) of obese pregnant 
(4.011±0.152) were significantly higher than the lean pregnant (3.488±0.175) 
.However the HDL (mmol/l) of lean pregnant (1.744±0.069) were higher than the 
obese pregnant (1.671±0.07) but were not statistically significant (Fig.3.2). 
 
3.5 Fetal Glucose and lipid concentration (lean and obese pregnant) 
Fetal glucose levels quantification and lipid profile analysis in the cord serum of lean 
and obese pregnant women were analysed using automated chemical analyser (Fig 
3.3) .The glucose levels (mmol/l) of fetuses of obese pregnant women (3.869±0.072) 
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were slightly elevated compared to fetuses of lean pregnant women (3.732±0.067) 
and are not significant. The total cholesterol levels of fetuses of obese pregnant 
(1.734 mmol/l±0.059) were significantly higher than that of the lean pregnant 
(1.562mmol/l±0.059). Similarly, the triglycerides (mmol/l) of fetuses of obese 
pregnant (0.269±0.02) were significantly higher than that of the lean pregnant 
(0.209±0.013). Similarly, the LDL (mmol/l) of fetuses of obese pregnant 
(0.879±0.044) was significantly higher than that of the lean pregnant (0.722±0.028). 
However the HDL (mmol/l) levels of fetuses of lean pregnant (0.813±0.042) were 
higher than the fetuses obese pregnant (0.732±0.039) and are not statistically 
significant. 
 
 3.6 Maternal and Fetal Insulin concentration (lean and obese pregnant) 
The Insulin levels (µIU/ml) were measured in the serum using ELISA were 
significantly (p=0.008) elevated in obese pregnant (17.815±1.782) compared to lean 
pregnant women (11.871±1.267). However, the insulin levels were not statistically 
different in the cord bloods of babies born to obese pregnant women (11.4±2.099) 
compared to the lean pregnant women (8.976±0.763) (Fig.3.4). 
 
 3.7 Maternal and Fetal Leptin concentration (lean and obese pregnant) 
The Leptin levels (ng/ml) were measured in the plasma using ELISA were 
significantly (p<0.0001) elevated in obese pregnant (48.6031±2.801) compared to 
lean pregnant women (23.933±2.66). Similarly, the leptin levels were statistically 
different (p<0.0007) in the cord bloods of babies born to obese pregnant women 
(4.862 ±5.408) compared to babies of the lean pregnant women (2.674±2.143) 
(Fig.3.5). 
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 3.8 Maternal and Fetal NEFA concentration (lean and obese pregnant) 
The NEFA levels (nmol/µl or mM) were measured in the plasma were significantly 
(p<0.05) elevated in obese pregnant women (1.348±0.068) compared to lean 
pregnant women (1.088±0.12). Similarly, the NEFA levels were statistically different 
(p<0.05) in the cord bloods of babies born to obese pregnant women (0.194 ±0.025) 
compared to the babies of lean pregnant women (0.123±0.012) (Fig.3.6). 
 
 3.9 Plasma adipsin is significantly elevated in obese pregnancy: 
The adipsin levels were measured in the plasma (pg/ml) using ELISA were found to 
be significantly (p <0.05) elevated in obese pregnant women (843.42pg/ml ± 33.14) 
compared to lean pregnant women (720.63pg/ml ± 33.13). However, cord blood 
samples revealed significantly higher levels of adipsin than maternal samples. 
Furthermore babies of obese pregnant women  were significantly(p<0.05) higher 
levels of adipsin (1663.78 ± 52.76 pg/ml) in the cord bloods as compared to babies of 
lean pregnant women (1354.37 ± 33.82 pg/ml) (Fig.3.7). 
 
3.10 Secretion of adipsin by human placenta- lean and obese pregnant 
Adipsin was found to be secreted from the adipose tissue explants as expected, with 
tissues from obese patients producing significantly(p<0.05) more adipsin per mg 
weight (790.27 ± 64.60 pg/ml/mg) as compared to adipose tissue from lean mothers 
(504.74 ± 31.94 pg/ml/mg) (Fig.3.8). Surprisingly, in addition to the secretion of 
adipsin in the adipose tissue explants, adipsin secretion from placental explants was 
identified, which was significantly(p < 0.04) greater in placental explants from obese 
pregnant women (546.0 ± 44.38 pg/ml/mg) than from placental explants from lean 
pregnant women (284.56 ± 43 pg/ml/mg) (Fig.3.8). 
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3.11 Plasma ASP is significantly elevated in obese pregnancy.  
The ASP levels in plasma using ELISA were found to be significantly (p <0.05) 
elevated in obese pregnant women (608.70 ± 67.15ng/ml) compared to lean pregnant 
women (420.30 ± 39.98ng/ml) (Fig.3.9). In contrast to adipsin, the ASP levels in the 
cord blood samples were within a similar range to the maternal samples, but 
offspring of obese pregnant women had significantly (p <0.05) greater levels of cord 
blood ASP (354.48 ± 12.12ng/ml) than the offspring of lean pregnant women 
(302.63 ± 14.98ng/ml). 
 
3.12 Secretion of ASP by human placenta- lean and obese pregnant 
Similar analyses utilizing obese and lean pregnant explants of placenta and adipose 
tissue were performed to identify, whether the human placenta was also producing 
ASP. ASP secretion was identified from both adipose and placental explants.  
Moreover, ASP secretion was significantly greater from placental tissues as 
compared to the adipose tissue explants. The ASP levels in the medium of placental 
tissues of obese pregnant women (5485.74 ± 163.32ng/ml/mg) were significantly 
(p<0.05) higher than those of lean pregnant women (2399.16 ± 181.83ng/ml/mg) 
(Fig.3.10). Although to a much lesser extent, ASP secretion from adipose tissues of 
obese pregnant women (1508.40± 659.65ng/ml/mg) was higher than ASP secretion 
from adipose tissues of lean pregnant women (807.21 ± 254.8ng/ml/mg). 
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Table 3.1 Anthropometric and biochemical characteristics between Normal (Lean) 
and obese pregnant women. 
 
 
Characteristics Normal  (Lean) pregnant 
women(n=35) 
Obese pregnant women 
(n=39) 
Maternal age (years) 32 (18-44) 32.487 (22-47) 
Booking BMI (Kg/m2) 23.477 (20 - 24.9) 33.723 (30 - 46) 
Mean Gestational Age at 
delivery (weeks) 
39+2 39+2 
Fasting status 35/35 39/39 
OGTT (26-28 weeks) Normal 35/35 Normal 39/39 
Birth weight 3.51Kg ±  0.04 3.61Kg ± 0.03 
HOMA-IR 
Mother/Baby 
1.84 ± 0.283/1.365 ± 0.08 2.436± 0.21/2.171 ± 0.288 
 
 
Body Mass Index (BMI), Oral Glucose Tolerance Test (OGTT), Homeostatic Model 
Assessment-Insulin resistance (HOMA-IR), Number of patients (n).Data are 
presented as mean ± range. 
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Table 3.2 Maternal and fetal biochemical profiles between Lean and obese pregnant 
women. 
 Maternal Fetal 
Biochemical 
parameters 
Lean 
(n=34) 
Obese 
(n=39) 
p-value Lean 
(n=34) 
Obese 
(n=39) 
p-value 
Glucose 
(mmol/l) 
4.288 ± 
0.05 
4.279 ± 
0.098 
0.938
 
3.732 ±0.07 3.87±0.07 0.168 
TGL 
(mmol/l) 
2.494 ± 
0.12 
2.887 ± 0.14 0.037
* 
0.209±0.1 0.26 ± 0.02 0.014
* 
Total 
cholesterol 
(mmol/l) 
6.086 ± 
0.24 
6.743 ± 
0.194 
0.036
* 
1.562 ±0.06 1.734± 0.06 0.043
* 
HDL (mmol/l) 1.74 ± 
0.069 
1.671 ± 0.07 0.459 0.81±0.042 0.732 ±0.04 0.163 
LDL  
(mmol/l) 
3.49 ± 
0.175 
4.011 ± 
0.152 
0.029
* 
0.72 ±0.028 0.879 ±0.04 0.003
* 
Insulin 
(µIU/ml) 
11.87 ± 
1.27 
17.82 ± 
1.782 
0.008
* 8.98 ±0.763 11.4 ±2.099 0.283 
Leptin 
(ng/ml) 
23.933±2.
66 
 
48.6031±2.8
0 
 
 
0.0001* 2.674±2.14 
 
 
4.862 ±5.41 
 
 
0.0007* 
Triglycerides (TGL), High Density Lipoprotein cholesterol (HDL), Low Density 
Lipoprotein cholesterol (LDL), Lean-Pregnant women with normal BMI, Obese-
Pregnant women with high BMI.  Data are presented as mean ± SEM.*p<0.05 
significant compared to lean pregnant women. 
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Figure 3.1 
 
H o m e o s ta s is  m o d e l a s s e s m e n t  o f  in s u lin  r e s is ta n c e
H O M A -IR (H o m e o s ta s is  a s s e s m e n t o f  in s u lin  re s is ta n c e ) in  m a te rn a l a n d  fe ta l s a m p le s  o f
 le a n  a n d  o b e s e  .D a ta  a re  s h o w n  in  m e a n  a n d  s ta n d a rd  e rro r  o f  m e a n  (S E M )
 *p < 0 .0 5  c o m p a re d  w ith  le a n .
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Figure 3.2 
 
M a te rn a l G lu c o s e  a n d  L ip id   c o n c e n tra t io n   in  s e r u m
M a te rn a l G lu c o s e  a n d  L ip id  C o n c e n tra t io n s  in  s e ru m  o f le a n  a n d  o b e s e  g ro u p s .D a ta  a re  s h o w n  a s
m e a n  a n d  s ta n d a rd  e rro r  o f  m e a n (S E M )
*   p < 0 .0 5  c o m p a re d  w ith  le a n
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Figure 3.3 
 
F e ta l G lu c o s e  a n d  L ip id s   c o n c e n tra t io n   in  s e r u m
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g ro u p s .D a ta  a re  s h o w n  a s  m e a n  a n d  s ta n d a rd  e rro r  o f  m e a n (S E M )
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Figure 3.4 
 
In s u lin  c o n c e n tr a t io n   in  s e r u m
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M a te rn a l a n d  F e ta l in s u lin  c o n ce n tra t io n  in  le a n  a n d  o b e se  g ro u p s
u s in g  E L IS A .D a ta  a re  s h o w n  a s  m e a n  a n d  s ta n d a rd  e rro r o f
m e a n (S E M ).*p < 0 .0 5  c o m p a re d  w ith  le a n
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Figure 3.5 
 
L e p tin  c o n c e n tr a t io n  in  p la s m a
L e p tin  c o n c e n tra t io n  in  m a te rn a l a n d  fe ta l s a m p le s  o f  le a n  a n d  o b e s e  .D a ta  a re  s h o w n  in  m e a n  a n d
s ta n d a rd  e r ro r  o f  m e a n  (S E M ) *p < 0 .0 5  c o m p a re d  w ith  le a n .
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Figure 3.6 
 
N E F A  c o n c e n tra t io n  in  p la s m a
N E F A (N o n  E s te r if ie d  fre e  fa tty  a c id )  c o n c e n tra t io n  in  m a te rn a l a n d  fe ta l s a m p le s  o f
 le a n  a n d  o b e s e  .D a ta  a re  s h o w n  in  m e a n  a n d  s ta n d a rd  e rro r  o f  m e a n  (S E M )
 *p < 0 .0 5  c o m p a re d  w ith  le a n .
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Figure 3.7 
 
A d ip s in  c o n c e n tr a t io n  in  p la s m a
P la s m a  a d ip s in  c o n c e n tra tio n  in   m a te rn a l a n d  fe ta l s a m p le s  o f  le a n  a n d  o b e s e  u s in g  E L IS A .D a ta
s h o w n  a s  m e a n  a n d  s ta n d a rd  e rro r  o f  m e a n (S E M ) *p < 0 .0 5  c o m p a re d  w ith  le a n  p re g n a n t  s a m p le s .
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Figure 3.8 
 
A d ip s in  c o n c e n tr a t io n   in  e x p la n ts
A d ip s in  C o n c e n tra t io n  in  t is s u e  e x p la n ts  o f  p la c e n ta  &  fa t  in  p re g n a n t w o m e n
w ith  le a n  &  o b e s e  u s in g  E L IS A .D a ta  a re  s h o w n  a s  m e a n  a n d  s ta n d a rd  e rro r  o f  m e a n (S E M ). *p < 0 .0 5
c o m p a re d  w ith  le a n .
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Figure 3.9 
 
A S P  c o n c e n tra t io n   in  p la s m a
P la s m a  A S P (c 3 a  d e s  a rg )  c o n c e n tra t io n  in  m a te rn a l a n d  fe ta l s a m p le s  o f le a n  &  o b e s e  u s in g
E L IS A .D a ta  a re  s h o w n  in  m e a n  a n d  s ta n d a rd  e rro r  o f  m e a n  (S E M ) *p < 0 .0 5  c o m p a re d  w ith  le a n
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Figure 3.10 
 
A S P  c o n c e n tra t io n   in  e x p la n ts
A S P   C o n c e n tra t io n  in  t is s u e  e x p la n ts  o f  p la c e n ta  &  fa t  in  p re g n a n t w o m e n  w ith  n o rm a l B M I &  h ig h B M I
u s in g  E L IS A
D a ta  a re  s h o w n  a s  m e a n  a n d  s ta n d a rd  e rro r  o f  m e a n (S E M ). *p < 0 .0 5  c o m p a re d  w ith  p re g n a n t  w o m e n
w ith  n o rm a l B M I.D a y 2 -a fte r  4 8  h rs  o f  in c u b a tio n  o f th e  c o n d it io n e d  m e d iu m .
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 4.1 Anthropometric and biochemical characteristics: (Lean pregnant and GDM 
pregnant) 
The anthropometric and metabolic characteristics between lean pregnant and GDM 
pregnant are presented in the Table 4.1.The characteristics of maternal age in years, 
booking BMI in kg/m
2
, mean gestational age at delivery in weeks, fasting status and 
OGTT in 26-28 wks between lean pregnant and GDM pregnant are tabulated. The 
booking BMI of GDM pregnant (34.4 kg/m
2
) were significantly higher than the lean 
pregnant (23.477kg/m
2
). The birth-weight of GDM offspring (3.86 + 0.08) were 
significantly higher than the babies of lean pregnant (3.51kg±0.04).The HOMA-IR 
values were calculated  which were found to be  significantly elevated in GDM 
pregnant women  and their fetuses as measured in cord blood compared to lean 
pregnant women  and their fetuses. 
 
 4.2 Maternal and fetal biochemical profiles (Lean and GDM pregnant women) 
The maternal and fetal biochemical profiles between lean and GDM are summarized 
in Table 4.2. There were  statistically significant differences (p<0.05) found in the 
levels of glucose, triglycerides, HDL and LDL which were all elevated in GDM 
mothers as well as their corresponding  fetal cord bloods compared to the lean 
pregnant mothers and their babies. However, no statistically significant differences 
were found in the levels of total cholesterol, in GDM pregnant mothers but it was 
found to be significantly elevated in their corresponding fetal cord bloods compared 
to the lean pregnant mothers and their babies. The Insulin levels were significantly 
(p<0.04) elevated in GDM mothers as well as their corresponding fetal cord bloods 
compared to lean pregnant women and their babies. The Leptin levels were 
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significantly (p<0.0004) elevated in GDM mothers as well as their corresponding 
fetal cord bloods (p<0.0002) compared to lean pregnant women and their babies.  
 
  4.3 Maternal and Fetal HOMA-IR (lean and GDM pregnant) 
The HOMA-IR values were calculated, which were found to be elevated in GDM 
pregnant women (3.5541 ±0.184) compared to lean pregnant women (1.84±0.283) 
(Fig.4.1). Similarly, the HOMA-IR values were also elevated in the offspring of 
GDM pregnant as measured in cord blood (2.39 ±0.16) compared to babies of lean 
pregnant women (1.365±0.08). 
 
 4.4 Maternal Glucose and lipid concentration (lean and GDM pregnant) 
Maternal glucose levels quantification and lipid profile analysis in serum between 
lean and GDM pregnant women were performed using automated chemical analyser 
(Fig.4.2). The glucose of GDM (4.783 mmol/l±0.265) were significantly higher than 
the lean pregnant (4.288mmol/l±0.055). Similarly, the triglycerides (mmol/l) of 
GDM (2.837±0.21) were significantly higher than the lean pregnant (2.494±0.12). 
Similarly, the LDL (mmol/l) levels of GDM (3.585±0.3) were significantly higher 
than the lean pregnant (3.488±0.175). Likewise, the HDL (mmol/l) of lean pregnant 
(1.744 ± 0.069) was significantly higher than the GDM pregnant (1.281 ± 0.1). 
Similarly, the total cholesterol (mmol/l) of GDM (6.393± 0.343) were higher than the 
lean pregnant (6.086±0.235) but were not significant (Fig.4.2). 
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 4.5 Fetal Glucose and lipid concentration (lean and GDM pregnant) 
Fetal glucose levels quantification and lipid profile analysis in the cord serum of lean 
and GDM pregnant women were analysed using automated chemical analyser 
(Fig.4.3) .The glucose levels (mmol/l) of babies of GDM pregnant women 
(4.478mmlo/l±0.357) were significantly (p<0.05*)elevated compared to babies of 
lean pregnant women (3.732±0.067). The total cholesterol levels of babies of GDM 
pregnant (1.653 ± 0.124) were higher than that of the lean pregnant 
(1.562mmol/l±0.059) and are significant (p<0.05). Similarly, the triglycerides 
(mmol/l) of babies of GDM pregnant (0.2412±0.0169) were significantly (p<0.012) 
higher than that of the lean pregnant (0.209±0.013). Similarly, the LDL (mmol/l) of 
babies of GDM pregnant (0.852±0.06) were significantly (p<0.03*) higher than that 
of the lean pregnant (0.722±0.028). However, the HDL (mmol/l) levels of babies of 
lean pregnant (0.813±0.042) were significantly higher than the babies GDM pregnant 
(0.631±0.036; p<0.002) (Fig.4.3). 
 
 4.6 Maternal and Fetal Insulin concentration (lean and GDM pregnant) 
The Insulin levels (µIU/ml) were measured in the serum were significantly (p<0.04) 
elevated in GDM mothers (20.013±3.463) compared to lean pregnant women 
(11.871±1.267) (Fig.4.4). Similarly, the insulin levels were statistically different 
(p<0.05) in the cord bloods of babies born to GDM pregnant women (12.79±2.282) 
compared to the lean pregnant women (8.976±0.763). 
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 4.7 Maternal and Fetal Leptin concentration (lean and GDM pregnant) 
The Leptin levels (ng/ml) were measured in the plasma were significantly 
(p<0.0004) elevated in GDM pregnant women (42.24±2.621) compared to lean 
pregnant women (23.933±2.66) (Fig.4.5). Similarly, the leptin levels were 
statistically different (p<0.0002) in the cord bloods of babies born to GDM pregnant 
women (4.133 ±0.255) compared to the lean pregnant women (2.674±2.143). 
 
 4.8 Maternal and Fetal NEFA concentration (lean and GDM pregnant) 
The NEFA levels (nmol/µl or mM) were measured in the plasma were significantly 
(p<0.0001) elevated in GDM pregnant women (2.1505±0.2004) compared to lean 
pregnant women (1.088±0.12) (Fig.4.6). Similarly, the NEFA levels were 
statistically different (p<0.0078) in the cord bloods of babies born to GDM pregnant 
women (0.311±0.1104) compared to the babies of lean pregnant women 
(0.123±0.012) (Fig.4.6). 
 
 4.9 Plasma adipsin is significantly elevated in GDM pregnancy: 
The adipsin levels in plasma (pg/ml) were found to be significantly (p <0.05) 
elevated in GDM pregnant women (865.59 ± 56.304) compared to lean pregnant 
women (720.63 ± 33.13) (Fig.4.7). Cord blood samples revealed significantly higher 
levels of adipsin than maternal samples. Furthermore babies born to GDM pregnant 
women  showed significantly(p<0.05) higher levels of adipsin (1576.99 ± 90.888 
pg/ml) in the cord bloods as compared to babies of lean pregnant women (1354.37 ± 
33.82 pg/ml) (Fig.4.7). 
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 4.10 Secretion of adipsin by human placenta-lean and GDM pregnant 
As expected, adipsin was found to be secreted from the adipose tissue, with tissues 
from GDM patients producing significantly(p<0.05) more adipsin per mg weight 
(691.393 ± 17.462 pg/ml/mg) as compared to adipose tissue from lean mothers 
(504.74 ± 31.94 pg/ml/mg) (Fig.4.8). 
 Surprisingly, adipsin secretion from placental explants was identified, which was 
significantly (p < 0.04) greater in placentae from GDM patients (441.654 ± 38.1206 
pg/ml/mg) than from placentae from lean patients (284.56 ± 43 pg/ml/mg) (Fig.4.8). 
 
 4.11 Plasma ASP is elevated in GDM pregnancy.  
The ASP levels in plasma using ELISA were found to be  elevated in GDM pregnant 
women (458.389 ± 20.982 ng/ml) compared to lean pregnant women (420.30 ± 39.98 
ng/ml) and were not significant (Fig.4.9). In contrast to adipsin, the ASP levels in the 
cord blood samples were within a similar range to the maternal samples, but 
offspring of GDM pregnant women had  greater levels of cord blood ASP (336.528 ± 
29.754 ng/ml) than the offspring of lean pregnant women (302.63 ± 14.98 ng/ml) and 
were not significant (Fig.4.9). 
 
 4.12 Secretion of ASP by human placenta-lean and GDM pregnant 
 Similar analyses utilizing obese and lean pregnant explants of placenta and adipose 
tissue were performed to identify whether the GDM placenta was also producing 
ASP (Fig.4.10). ASP secretion was identified from both adipose and placental 
explants. Moreover, ASP secretion was significantly greater from placental tissues as 
compared to the adipose tissue explants. The ASP levels in the medium of placental 
tissues of GDM pregnant women (4813.69 ± 153.76 ng/ml/mg) were significantly 
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(p<0.05) higher than those of lean pregnant women (2399.16 ± 181.83 ng/ml/mg) 
(Fig.4.10). Although ASP secretion from adipose tissues of lean pregnant women 
was higher (807.21 ± 254.8 ng/ml/mg) than ASP secretion from adipose tissues of 
GDM pregnant women (644.145 ± 105.78 ng/ml/mg) but was not significant. 
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Table 4.1 Anthropometric and biochemical characteristics between Normal (Lean) 
and GDM pregnant women. 
 
 
Characteristics Normal (Mean + Range) n=35 GDM (Mean + Range) 
n=18 
Maternal age (yrs) 32 (18-44) 34.4 (26-47) 
Booking BMI (Kg/m2) 23.477 (20 - 24.9) 31.16 (23-46) 
Mean Gestational Age 
at delivery (wks) 
39+2 39+2 
Fasting status 35/35 18/18 
OGTT (26-28 weeks) Normal 35/35 Abnormal 18/18 
Birth weight 3.51Kg ±  0.04 3.86 Kg ± 0.08 
HOMA-IR 
Mother/Baby 
1.84 ± 0.283/1.365 ± 0.08 3.5541 ±0.184/2.39 ±0.166 
 
 
Body Mass Index (BMI), Oral Glucose Tolerance Test(OGTT), Homeostasis Model 
Assessment-Insulin resistance (HOMA-IR),Number of patients(n).Data are presented 
as mean+range. 
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Table 4.2 Maternal and fetal biochemical profiles between Lean and GDM pregnant 
women 
. 
 Maternal Fetal 
Biochemical 
parameters 
Lean 
(n=34) 
GDM 
(n=18) 
p-value Lean 
(n=34) 
GDM 
(n=18) 
p-
value 
Glucose 
(mmol/l) 
4.288 ± 
0.055 
4.783 ± 
0.265 
0.04*
 
3.732 ± 
0.067 
4.478 ± 
0.357 
0.05* 
TGL 
(mmol/l) 
2.494 ± 
0.12 
2.837 ± 
0.21 
0.037
* 
0.209 ± 
0.013 
0.241 ± 
0.02 
0.012
* 
Total 
cholesterol 
(mmol/l) 
6.086 ± 
0.235 
6.393 ± 
0.343 
0.202
 
1.562 ± 
0.059 
1.653 ± 
0.124 
0.05
* 
HDL (mmol/l) 
1.744 ± 
0.069 
1.281 ± 0.1 0.0004* 
0.813 ± 
0.042 
0.631 ± 
0.036 
0.002* 
LDL  
(mmol/l) 
3.488 ± 
0.175 
3.585 ± 0.3 0.03
* 
0.722 ± 
0.028 
0.852 ± 
0.061 
0.03
* 
Insulin 
(µIU/ml) 
11.871 ± 
1.267 
20.013 ± 
3.463 
0.04* 
8.976 ± 
0.763 
12.79 ± 
2.282 
0.05* 
Leptin 
(ng/ml) 
23.933±2.
66 
 
42.24±2.62
1 
 
 
0.0004* 
2.674±2.143 
 
 
4.133 
±0.255 
 
 
0.0002
* 
 
Triglycerides(TGL),High Density Lipoprotein cholesterol(HDL),Low Density 
Lipoprotein cholesterol(LDL),Lean-Pregnant women with normal BMI,GDM-
Pregnant women with gestational Diabetes. Data are presented as 
mean±SEM.*p<0.05 significant compared to lean pregnant women. 
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Figure 4.1 
 
H o m e o s ta s is  m o d e l a s s e s m e n t  o f  in s u lin  r e s is ta n c e
H O M A -IR (H o m e o s ta s is  a s s e s m e n t o f  in s u lin  re s is ta n c e ) in  m a te rn a l a n d  fe ta l s a m p le s  o f
 le a n  a n d  G D M  .D a ta  a re  s h o w n  in  m e a n  a n d  s ta n d a rd  e rro r  o f  m e a n  (S E M )
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Figure 4.2 
 
M a te rn a l G lu c o s e  a n d  L ip id   c o n c e n tra t io n   in  s e r u m
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Figure 4.3 
 
F e ta l G lu c o s e  a n d  L ip id s   c o n c e n tra t io n   in  s e r u m
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Figure 4.4 
 
In s u lin  c o n c e n tr a t io n   in  s e r u m
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Figure 4.5 
 
L e p tin  c o n c e n tr a t io n  in  p la s m a
L e p tin  c o n c e n tra t io n  in  m a te rn a l a n d  fe ta l s a m p le s  o f  le a n  a n d  G D M  .D a ta  a re  s h o w n  in  m e a n  a n d
s ta n d a rd  e r ro r  o f  m e a n  (S E M ) *p < 0 .0 5  c o m p a re d  w ith  le a n .
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Figure 4.6 
 
N E F A  c o n c e n tra t io n  in  p la s m a
N E F A (N o n  E s te r if ie d  fre e  fa tty  a c id )  c o n c e n tra t io n  in  m a te rn a l a n d  fe ta l s a m p le s  o f
 le a n  a n d  G D M  .D a ta  a re  s h o w n  in  m e a n  a n d  s ta n d a rd  e rro r  o f  m e a n  (S E M )
 *p < 0 .0 5  c o m p a re d  w ith  le a n .
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Figure 4.7 
 
A d ip s in  c o n c e n tr a t io n  in  p la s m a
P la s m a  a d ip s in  c o n c e n tra tio n  in  m a te rn a l a n d  fe ta l s a m p le s  o f   le a n  a n d  G D M   u s in g  E L IS A .D a ta
s h o w n  a s  m e a n  a n d  s ta n d a rd  e rro r  o f  m e a n (S E M ) *p < 0 .0 5  c o m p a re d  w ith  le a n .
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Figure 4.8 
 
A d ip s in  c o n c e n tr a t io n   in  e x p la n ts
A d ip s in  C o n c e n tra t io n  in  t is s u e  e x p la n ts  o f  p la c e n ta  &  fa t  in  p re g n a n t w o m e n
w ith  n o rm a l B M I & G D M  u s in g  E L IS A .D a ta  a re  s h o w n  a s  m e a n  a n d  s ta n d a rd  e rro r  o f  m e a n (S E M ).
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Figure 4.9 
 
A S P  c o n c e n tra t io n   in  p la s m a
P la s m a  A S P (c 3 a  d e s  a rg ) c o n c e n tra t io n  in  m a te rn a l a n d  fe ta l s a m p le s  o f  le a n  a n d  G D M  u s in g
E L IS A .D a ta  a re  s h o w n  in  m e a n  a n d  s ta n d a rd  e rro r  o f  m e a n  (S E M )
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Figure 4.10 
 
A S P  c o n c e n tra t io n   in  e x p la n ts
A S P   C o n c e n tra t io n  in  t is s u e  e x p la n ts  o f  p la c e n ta  &  fa t  in  p re g n a n t w o m e n  w ith  n o rm a l B M I & G D M
u s in g  E L IS A
D a ta  a re  s h o w n  a s  m e a n  a n d  s ta n d a rd  e rro r  o f  m e a n (S E M ). *p < 0 .0 5  c o m p a re d  w ith  p re g n a n t  w o m e n
w ith  n o rm a l B M I.D a y 2 -a fte r  4 8  h rs  o f  in c u b a tio n  o f th e  c o n d it io n e d  m e d iu m .
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CHAPTER 5 
 
RESULTS 
 
Differences between lean, obese and GDM pregnancies 
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RESULTS: 
 5.1 Differences between lean, obese and GDM pregnant women 
Differences between lean, obese and GDM pregnant women are tabulated in Table 
5.1. The levels of glucose were similar between lean and obese pregnant, but it was 
elevated in GDM pregnant women. However, the insulin levels were elevated in both 
obese pregnant and GDM pregnant compared to lean pregnant. Similarly, the serum 
TGL level were found to be elevated in obese pregnant than lean and GDM pregnant 
women. Plasma adipsin levels were found to be elevated in obese pregnant 
(843.42pg/ml±33.14) compared to lean pregnant (720.63 pg/ml±21.77), but the 
levels were slightly elevated in GDM pregnant (865.59 pg/ml ±56.304) than obese 
pregnant women. Plasma ASP concentration were elevated in obese pregnant 
(608.70 ng/ml±67.15) than lean pregnant (420.30 ng/ml ±39.98) and GDM (458.39 
ng/ml ±20.98) (Table 5.1). 
 
5.2 Effect of insulin on adipsin release 
Human placentas and subcutaneous fat were obtained from lean pregnant (n=4), 
obese pregnant (n=4) and GDM pregnant (n=4) were incubated in the presence of 
insulin as well as in the absence of insulin. 
The adipsin release in adipose tissue as expected was found to be significantly more 
in obese pregnant (790.27 pg/mg/ml ± 64.6) than lean (504.74 pg/mg/ml ± 31.94) 
and GDM pregnant (691.39 pg/mg/ml ±17.43) (Fig.5.1&Table 5.2).However, when 
adipose explants were treated with insulin the release of adipsin were found to be 
elevated in obese pregnant (712 ±32.93pg/mg/ml) than lean pregnant 
(611.39pg/mg/ml ± 83.42), but the release were found to be lower in GDM 
(540.21pg/mg/ml ± 70.52) than obese pregnant and lean pregnant and were not 
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significant.  Moreover, when the adipose explants of lean pregnant were treated with 
insulin the release of adipsin were increased than the release from non-insulin treated 
adipose explants, whereas the adipose explants of  obese pregnant and GDM were 
treated with insulin, the release of adipsin were found to be decreased than the non-
insulin treated adipose explants(Fig 5.1). 
 
Similar analyses on placental explants were performed. The adipsin release in 
placental tissues were found to be significantly more in obese pregnant (546 ± 
44.38pg/mg/ml) than lean (284.56pg/mg/ml ± 43) and GDM pregnant (441.65 
pg/mg/ml ±38.121) (Fig 5.1&Table 5.2).  However, when placental explants were 
treated with insulin the release of adipsin were found to be elevated in obese 
pregnant (689.53 ±28.23pg/mg/ml) than lean pregnant (393.19pg/mg/ml ± 24.18) , 
but the release were found to be lower in GDM (342 pg/mg/ml ± 10) than obese 
pregnant and lean pregnant and were not significant (Fig 5.1).  Furthermore, when 
the placental explants of obese pregnant and lean pregnant were treated with insulin 
the release of adipsin were increased than the  non-insulin treated placental tissues, 
whereas the placental explants of GDM treated with insulin, the release of adipsin 
were found to be decreased than the non-insulin treated  GDM placental explants(Fig 
5.1). 
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      Table 5.1 
Differences between lean, obese and GDM pregnant women 
 Lean pregnant Obese pregnant GDM 
Glucose 
(mmol/l) 
 
4.288 ± 0.055 
 
4.28±0.09 
4.783 ± 0.265 
Insulin 
(µIU/ml) 
11.871 ± 1.267 17.82±1.782 
20.013 ± 3.463 
TGL 
(mmol/l) 
2.494 ± 0.12 2.89 ±0.14 
2.837 ± 0.21 
[Adipsin] 
pg/ml 
 
720.63±21.77 
 
843.42±33.14 
 
865.59±56.304 
[ASP] 
ng/ml 
 
420.30±39.98 
 
608.70±67.15 
 
458.39±20.98 
 
TGL-Triglycerides, ASP-Acylation stimulating hormone. Data are expressed in 
mean ± SEM (standard error of mean). 
 
 
 
 
110 
 
 
Table 5.2 
Adipsin secretion in tissue explants-placenta and subcutaneous fat-treated 
without and with Insulin 
 Lean pregnant 
(n=4) 
Obese pregnant 
(n=4) 
GDM 
(n=4) 
Adipsin secretion in 
placental explants 
(pg/mg/ml) 
284.56 ± 43 546 ± 44.38 441.65 ±38.121 
Adipsin secretion in 
placental explants 
treated with insulin 
(pg/mg/ml) 
393.19 ± 24.18 689.53 ± 28.23 342 ±10 
Adipsin secretion in 
fat explants 
(pg/mg/ml) 
504.74 ±31.94 790.27 ± 64.6 691.39 ± 17.43 
Adipsin secretion in 
fat  explants treated 
with insulin 
(pg/mg/ml) 
611.39 ± 83.42 712 ±32.93 540.21 ± 70.52 
 
Data are expressed in mean ± SEM (standard error of mean). 
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Figure 5.1 
Adipsin concentration in explants 
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CHAPTER 6 
RESULTS 
 
Localization of Adipsin and ASP in Human Placenta  
 
And 
 
Identification of Adipsin and ASP in Hofbauer cells 
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6.1 Immuno histochemistry -Adipsin staining in the human placenta 
Utilizing immunohistochemistry, adipsin was localized in the placenta (fig.6.1a, 
6.1b, 6.1c &6.1d). Adipsin positive areas (fig.6.1c) were found in specific cells 
dispersed throughout the human placenta. Surprisingly, marked staining were seen in 
the peri-vascular area (fig.6.1d), suggesting that there would be higher levels of 
adipsin in proximity to the fetal vasculature. The distribution of these cells suggested 
that they would be either fibroblast or Hofbauer cells. 
6.2 Western Blotting: 
Antibody specificity was then confirmed using western blotting, with human adipose 
tissue as positive control.  Clear single band was visible at 28 kDa in adipose tissue 
as well as placental proteins (Fig.6.2). 
6.3 Hofbauer cells (placental macrophages) secrete both adipsin and ASP 
Having identified the human placenta as the one of the source of both adipsin and 
ASP, negative magnetic selection of cell types from the human placenta was 
performed as previously described in order to determine which cell type was 
responsible for the secretion of these molecules. To determine which cell types were 
positive for adipsin; individual cells were separated using magnetic beads. 
The fibroblasts, Cytotrophoblasts and Hofbauer cells (placental macrophages) from 
four human placentas were then cultured and were only able to detect minimal ASP 
or adipsin in either fibroblasts or CTs. However, clear secretion of both adipsin 
(49.75 pg/ml/10
6
 cells) (fig.6.3) and ASP (13.62 ng /ml/ 10
6
 cells) (fig.6.4) from 
placental macrophage (HBCs) were detected. 
6.4 Immunoflourescence: The dual staining of adipsin and CD206 on placental 
tissues showed co-localization (Fig6.5b). In contrast, no co-localization was 
observed for adipsin and CK7 (controls) (Fig6.5a).   
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Immuno histochemistry 
Adipsin staining in the human placenta 
 
 
Figure 6.1a 
Dispersion and positive areas of adipsin throughout the placenta 
 
 
 
 
 
Figure 6.1b 
Localization of Adipsin in placental tissue 
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Figure 6.1c 
Marked staining seen around peri-vascular area 
 
 
 
 
 
 
Figure 6.1d 
Marked staining with Adipsin in the peri-vascular areas in placental tissue 
 
 
 
 
 
 
 
116 
 
 
 
 
Figure 6.2 
Adipsin Western Blot 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 
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Figure 6.4 
 
A S P  c o n c e n tra t io n   in  p la c e n ta l m a c r o p h a g e s
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Figure 6.5a: CK7 and Adipsin dual staining on placental frozen sections 
(Adipsin=Red, CK7=Green)  
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Figure 6.5b: CD206 and Adipsin dual staining on placental frozen sections 
(Adipsin=Red, CD206=Green)  
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CHAPTER 7 
 
RESULTS 
 
Systematic Investigations of FGF21 in lean, obese and GDM Pregnancies 
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RESULTS: 
 7.1 Plasma FGF21 is significantly elevated in GDM pregnancy. 
Plasma FGF21 levels were found to be significantly elevated in GDM pregnant 
women (234.3pg/ml ± 30.698) compared to pregnant women with normal BMI 
(115.5pg/ml ± 31.768) (p<0.05) (Fig.7.1).  
However, plasma FGF21 concentration in obese pregnant women (148.87 pg/ml ± 
32.762) showed higher levels than the lean pregnant women and are not significant 
(Fig.7.1). 
  
7.2 FGF21 concentration in CSF in lean, obese and GDM pregnant women 
Having identified the levels of FGF21 in plasma in these three groups (lean, obese 
and GDM pregnant women), similar analyses was performed in their cerebrospinal 
fluids. Levels of FGF21 were found to be much lower in CSF than in maternal 
plasma (Fig .7.1&7.2) 
CSF FGF21 concentration were found to be slightly elevated in GDM pregnant 
women (96.2 pg/ml ± 0.419) compared to lean pregnant women (93.1 pg/ml ± 0.173) 
and obese pregnancy (94.3 pg/ml ± 0.125) but these failed to reach significance 
(Fig.7.2). 
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 7.3 CSF/Plasma FGF21 ratio in lean, obese and GDM pregnant women 
Having identified the levels of FGF21 in plasma and CSF in these three groups (lean, 
obese and GDM pregnant women), CSF/Plasma ratio was estimated.  Interestingly, 
CSF/Plasma FGF21 ratio was significantly lower in women with GDM (0.4 ± 0.02) 
compared to lean pregnant (0.8 ± 0.01) and obese pregnant women (0.6 ± 0.03); 
(p<0.05) (Fig.7.3). 
 
7.4 Secretion  of  FGF21 by human placenta 
Analyses on explants media of both placental and adipose tissue were performed to 
identify if human placenta was also producing FGF21, as human placenta secretes 
many adipose tissue related proteins.  As expected, adipose tissue (AT) secreted 
FGF21, with tissues from GDM patients producing slightly higher FGF21 per mg 
weight (0.215 pg/ml/mg ± 0.02) as compared to adipose tissue from lean mothers 
(0.1 pg/ml/mg ± 0.03) and obese pregnant patients (0.399 pg/ml /mg ± 0.01) and was 
not significant (Fig.7.4). 
In addition, FGF21 secretion from placental explants, which were lower in placenta 
explants from GDM pregnancy (0.2 pg/ml/mg ± 0.02) than from placenta from lean 
pregnancy patients (0.28 pg/ml/mg ± 0.03) and  placenta of obese pregnancy (0.48 
pg/ml/mg ± 0.02) these differences were significant (p<0.05) (Fig.7.4). 
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Figure 7.1 
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Figure 7.2 
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Figure 7.3 
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Figure 7.4 
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CHAPTER 8 
 
 GENERAL DISCUSSION 
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GENERAL DISCUSSION 
A potential role for the adipsin/Acylation Stimulating Protein pathway and FGF21 
in diabetic and obese pregnancy has been described.  The adipsin/ASP pathway 
increases lipogenesis by increasing the activity of DGAT1, decreasing the activity of 
lipoprotein lipase (LPL) and stimulating the GLUT4 transporter at the adipocyte 
membrane.  Adipsin has a physiological effect on the generation of ASP (also 
known as C3adesArg) together with C3 and factor B and this ASP has enzymatic 
activity in the synthesis and storage of triacylglycerol (Cianflone et al., 1994).   
Adipsin and ASP are well known to play significant roles in triglyceride storage, 
with elevations after high fat meals and both are known to be increased in 
circulating levels in association with obesity (Xia and Cianflone, 2003).   Adipsin 
and ASP appears to be of particular importance in states of insulin resistance (Xia 
and Cianflone, 2003).   Cianflone et al has described the adipsin/ASP pathway and 
shown that it raises triglyceride storage in adipocytes by increasing the activity of 
DGAT2 (Cianflone et al., 1994), decreasing the activity of hormone sensitive lipase 
(Yasruel et al., 1991), and increasing glucose transport (Cianflone et al., 2003)in the 
adipocytes.    
 As previously described in adipose tissue, my present data showed 
 a) That obese and GDM fetuses have higher levels of adipsin/ASP, 
 b) That the placenta is releasing adipsin/ASP and 
 c) That placental macrophages (Hofbauer cells) produce both components of this 
pathway. 
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More importantly, it has been shown that the receptor for ASP (C5L2) is expressed 
in the placenta (Cianflone et al., 1994) and circulating NEFA and TG levels in the 
fetus are significantly lower than in the mother suggesting that these molecules are 
having a biological effect.   Having hypothesized that, in concert with 
hyperglycemia, the adipsin/ASP pathway provides a mechanism by which increased 
fetal fat mass seen in the clinical situations described above can be explained. 
With regards to FGF21, a known insulin sensitizer; having identified lower 
CSF/plasma ratios of FGF21 in GDM pregnancy as well as having identified novel 
secretion of FGF21 from human placenta, with GDM explants producing less.  
These findings suggest a central mechanism of insulin resistance. 
As discussed in the introduction, gestational diabetes and obesity are major obstetric 
problems. Despite clear differences between these two diseases there are a number of 
common themes, namely insulin resistance, dyslipidemia and fetal macrosomia.  The 
later is particularly important since it predisposes to obesity and Type 2 diabetes later 
in life. 
Fetal macrosomia, which is principally due to increased fetal fat mass (Sparks, 
1984),  occurs in 3-10% of all pregnancies (Martin et al., 2006) and is responsible for 
significant risks particularly in the offspring of diabetic mothers as well as those who 
are obese (but who retain normal glycaemic control).   These include increased 
neonatal morbidity, neonatal injury, maternal injury and caesarean section (Spellacy 
et al., 1985).   Equally importantly these babies have a greater risk of obesity and 
Type 2 diabetes in later life (Hillier et al., 2007, Catalano et al., 2009a).   This issue 
is set to become more important as the incidence of maternal diabetes and obesity 
increases (Monte et al., 2011, Chen et al., 2012).   In diabetes, this increase in fetal 
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fat mass has been described to the Pedersen hypothesis, which suggests elevated 
maternal glycemia results in fetal hyperglycemia, which then predisposes the fetus to 
produce more insulin, leading to an increase in fat.   
 However, there are significant clinical findings that that the Pedersen hypothesis is 
not able to completely explain the issues, where, 
1. Those pregnancies with excellent glycemic control, and 
2. Those obese pregnancies, (in the absence of hyperglycemia) are complicated by 
fetal macrosomia.     
The babies of women with GDM have increased fetal fat mass (Sparks, 1984, 
Catalano et al., 2003b), as do the babies of women who are obese but not diabetic 
(Chu et al., 2009, Sewell et al., 2006) suggesting that hyperglycaemia, whilst 
important as a driver for intrauterine growth, may not wholly explain our common 
clinical observations.  
As alluded to above, despite excellent glycaemic control, a significant number of 
diabetic women will have a macrosomic fetus of about 3.5 times higher risk than the 
general population (Evers et al., 2002, Murphy et al., 2008), which appears to be a 
function of the pregravid BMI (Langer et al., 2005).   This finding is highlighted 
when considering that an overweight woman with well controlled GDM has a 50% 
higher chance of having a macrosomic baby compared to a lean woman with well-
controlled GDM.  
Obesity therefore, independently of diabetes,  predisposes to fetal macrosomia 
(doubling the risk without diabetes) (Langer et al., 2005).   While it is known that 
the increase in fetal macrosomia represents an increase in fetal fat mass,  how the 
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maternal environment enhances this lipid deposition in fetal tissues,  either in the 
absence of diabetes (as in obesity) or in well-controlled diabetes, is not completely 
understood.   It has been (Sparks, 1984)  hypothesized that genetic factors have a 
stronger relationship with fat-free mass (FFM), whereas the in utero environment 
may correlate better with fetal fat mass,  in accordance with the fetal origins of 
disease hypothesis, and in agreement with this,  the offspring of both GDM and 
obese women have increased risks of obesity and type 2 diabetes (Stothard et al., 
2009, Garcia-Vargas et al., 2012).   It is therefore important to identify common 
features between obese pregnancy and gestational diabetes (either well or poorly 
controlled) that might allow these discrepancies to be resolved, since these common 
features might impart some insight into a common mechanism. 
A common feature between both GDM women and overweight women without 
diabetes is maternal insulin resistance and consequent dyslipidemia.  Both GDM 
(Ramsay et al., 2002) and obese women without diabetes (Di Cianni et al., 2005) 
have higher circulating triglycerides (TG) and free fatty acids (FFA) than their 
respective lean controls.  Circulating TG have been noted to positively correlate 
with birth weight, independently of obesity and glucose (Kitajima et al., 2001) and 
maternal TG in early pregnancy are significantly correlated with birth weight (Nolan 
et al., 1995).  Maternal FFAs have been shown to correlate with fat mass at birth in 
well-controlled GDM populations (Schaefer-Graf et al., 2008) as well as in obese 
populations (Rao et al., 2012, Kitajima et al., 2001).  However, whilst significant 
research into the role of glycemia has been performed, relatively little work has 
explored the potential roles of dyslipidemia in macrosomia.  
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Clearly, there is a requirement for the substrates for adipogenesis to be present in the 
maternal circulation and a mechanism by which these substrates can be transported 
across the placenta.   As far as the former is concerned, all pregnancies are associated 
with a degree of hypertriglyceridemia as a result of the natural insulin resistance of 
pregnancy.  This hypertriglyceridemia is more marked in diabetic and obese 
pregnancies, which would enhance substrate availability to the fetus.  
This prompted me to explore alternate abnormal features of these pregnancies that 
are common and which might explain the fetal macrosomia seen in cases of diabetes 
with excellent glycemic control as well as obese pregnancies with normal glycemia.  
I have therefore considered that, in order for adipogenesis in the fetus to occur, two 
principal requirements must be met: 
1. The ability for the fetus to acquire these substrates in an insulin resistant 
environment. 
2. The presence of substrates in the maternal compartment. 
I have focussed on two mechanisms addressing each of these features.  In terms of 
the mechanisms by which the fetus might access these substrates, I have investigated 
the role of the adipsin/ ASP pathway.   In terms of the presence of substrates in the 
maternal compartment, I have assessed the role of FGF21. 
There are some substantial evidence that the circulating triglycerides (TG) and free 
fatty acids (FFA) are elevated in both GDM (Ramsay et al., 2002) and obese 
pregnancy without diabetes (Di Cianni et al., 2005) than their respective lean 
controls. 
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The mechanism by which fat crosses the placenta is not completely understood, yet 
this would be crucial if fetal macrosomia is to be explained. 
The previous paragraph has dealt with the evidence that these substrates are present, 
at higher levels, in the maternal compartment; however, little information is available 
about how the fetus acquires these substrates. 
 
Whilst the fetus requires fatty acids for appropriate brain development, and in the 
case of macrosomia, for adipose tissue formation, there is no mechanism by which 
maternal lipoproteins directly transfer across the placenta.  Indeed, the placenta 
possesses VLDL, LDL, HDL and LDL receptor related proteins, which allow these 
lipoproteins to be taken up by the placenta, where the actions of LPL, Phospholipase 
A2 and intracellular lipases on these allow fatty acids to be transferred to the fetus 
(Saleh et al., 2007, Contois et al., 1996). 
 
 The precise mechanisms by which these fatty acids are subsequently processed by 
the fetus are still unknown.  Adipsin levels in human pregnancy, an insulin resistant 
state, have not previously been reported, but the levels of ASP have been described, 
with the evidence of maternal ASP levels  increasing at late gestation (Saleh et al., 
2007),  increased maternal ASP with pregnancy weight gain (Sodowski et al., 2008), 
and increased fetal ASP in conjunction with the elevated maternal triglycerides 
(Saleh et al., 2008).  The transfer of lipids are regulated in the normal placenta from 
maternal to fetal blood through storage and release of FFA, which are important for 
steroid hormone precursors as well as for energy source for the growing embryo 
(Shafrir and Barash, 1987).   However, no previous reports have examined adipsin 
and ASP in obese pregnancy as well as in diabetic pregnancy.  
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This study has confirmed that both obese pregnant women and their fetuses in utero 
are insulin resistant as previously reported (Catalano et al., 2009b), as indicated by 
their elevated HOMA-IR values.  In agreement with other studies (Harmon et al., 
2011), significant differences in cholesterol, LDL and triglycerides with elevated 
levels are seen in obese mothers as well as in their corresponding cord bloods. 
 This study has also confirmed a marked difference in the concentration of fetal and 
maternal lipoproteins in pregnancies complicated by gestational diabetes as 
previously reported.  Other studies  have previously  shown a significant increase in 
LDL cholesterol and decrease in HDL cholesterol in the cord blood of type 1 
diabetes mellitus (Fordyce et al., 1983).   The observations made in this study has a 
similar trend of these two variable cholesterols but statistical significance was 
apparent, also significant hypertriglyceridemia was noted in venous cord sera of 
gestational diabetes.   The differences between these studies may be that Fordyce et 
al (Fordyce et al., 1983) did not analyze their data accounting for mode of delivery 
but in this study, all pregnant women were delivered in the morning by elective 
caesarean section under spinal anaesthesia after at least an eight hour fast.   Thus 
several studies have shown that maternal diabetes might affect the metabolic 
components of the plasma in the circulation of fetal compartment.   In this present 
study, both maternal obesity and maternal DM has been noted to exert an effect on 
lipoprotein concentration in fetal blood. 
In GDM pregnancies, plasma levels of NEFA were increased 2-fold compared with 
levels in the plasma of non-diabetic mothers.   Similarly, the cord blood levels of 
NEFA were lower compared with the levels in the diabetic mothers.   The increased 
concentration of NEFA in cord blood of GDM pregnancies than the cord blood of 
non-diabetic lean mothers might probably be caused by increased delivery from the 
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maternal circulation.  This could be explained from the previous reported studies that 
this increase in NEFA might be due to increased maternofetal gradient in diabetes 
(Thomas, 1987).   This profuse supply of NEFA to the fetus might be an important 
factor stimulating synthesis of other lipoproteins.   
In this study, the increase in maternal NEFA concentration in GDM could be 
explained by the relatively higher concentration of insulin in the peripheral blood 
circulation of gestational diabetes, as insulin induces the activity of lipoprotein lipase 
which increases the production of HDL precursors released during breakdown of 
triglycerides rich lipoproteins, which would explain this high concentration 
(Kissebah et al., 1976, Taskinen and Nikkila, 1979).   Noteworthy was the 
observation that circulating triglyceride and NEFA levels were significantly lower in 
the fetal compartment than compared to maternal, which might suggest a 
physiological action of ASP at the placental barrier.   To clarify this, further studies 
are needed in future. 
Several studies have reported that in the human placenta, leptin is produced and is 
secreted into both the maternal and fetal circulation (Masuzaki et al., 1997).   It has 
been reported that leptin levels in serum are generally related to adipose tissue mass 
and are correlated with body mass index and body fat mass in both pregnant 
(Highman et al., 1998), and non-pregnant adults (Considine et al., 1996).   During 
normal pregnancy, the concentration of leptin in serum is doubled (Hardie et al., 
1997, Highman et al., 1998).   
The observation made in this thesis confirms that circulating concentrations of leptin 
are significantly doubled in both obese pregnant and GDM compared to their lean 
pregnant controls.   Also the concentration of leptin was significantly higher in the 
cord bloods from obese pregnant as well as in the cord bloods from GDM.  This 
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study has also confirmed that obese pregnant women have significantly higher 
plasma leptin concentrations than non obese lean pregnant women as previously 
reported (Misra and Trudeau, 2011), as indicated by their elevated leptin values. 
A very important finding in this study was that circulating concentrations of adipsin 
in both obese pregnant and GDM mothers were increased compared to their lean 
pregnant controls.  Of particular interest was the finding that adipsin was 
significantly higher in the cord bloods than in the maternal circulation, with a 
significant elevation in the cord bloods from obese mothers as well as in the cord 
bloods from GDM mothers.   
In general, fasting ASP is strongly predictive of postprandial TG clearance in both 
men and women(Cianflone et al., 2004).   It has been reported that ASP is increased 
in diabetes, as well as insulin resistance, obesity, hyperthyroidism, cardiovascular 
disease and polycystic ovary syndrome (Cianflone et al., 2003, Maslowska et al., 
1999, Yang et al., 2006, Yu et al., 2006).  The findings with ASP in the mother’s 
blood also observations with higher levels noted in the obese pregnant groups than 
GDM pregnant groups. 
 
The release of adipsin and ASP may be affected by a number of factors, including 
glucose, GDM, hormones and inflammatory stimuli which are known to affect 
insulin sensitivity.   Due to the observed significantly increased fetal concentration of 
adipsin, together with elevated fetal concentration of ASP in both obese and GDM 
pregnancy has speculated whether the placenta might be a source of these molecules. 
I therefore also aimed to investigate the release of adipsin and ASP from placenta 
and adipose tissue.    
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Therefore paired explants experiments utilizing subcutaneous adipose tissue and 
placenta from lean pregnant, obese pregnant and GDM were carried out.  
Subcutaneous adipose tissue has previously been demonstrated to release similar 
amounts of adipsin than visceral tissue (Fain et al., 2007) and preliminary 
experiments confirmed these findings in our laboratory (data not shown).  
Interestingly, it has been demonstrated that placental explants secrete both adipsin 
and ASP into the media.  Of note, adipsin secretion from the placental explants was 
lower than that seen from the paired adipose tissue explants whilst ASP secretion 
from placental explants was substantially greater than that seen from adipose tissue.  
Whilst the secretion of adipsin from the placental explants was translated into higher 
levels of adipsin in cord blood, the extremely high levels of ASP released by 
placental explants did not translate into concomitantly higher levels of cord ASP, 
even though the cord bloods from obese mothers as well as GDM mothers did show 
a significant increase in ASP compared to lean pregnant controls.  These findings 
suggest that either the explants environment stimulates ASP production, perhaps as a 
result of an altered oxygen tension in the culture media or the placenta utilizes ASP 
locally.     
 In addition to this, when the placental explants of both lean and obese pregnant are 
treated with insulin, it has been observed that there is an increase in the adipsin 
release than non–insulin treated placental explants, although this failed to reach 
significance.   But in contrast, the adipsin release is found to be decreased in insulin 
treated GDM placental explants.  Whilst the secretion of adipsin from adipose tissue 
explants of lean pregnant treated with insulin is higher than non-insulin adipose 
explants.  Whereas, the adipsin release is observed to be decreased in both adipose 
explants of obese and GDM pregnant treated with insulin.    
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There are many possible reasons for these conflicting results between insulin and 
non-insulin treated tissue explants with respect to adipsin levels from lean, obese and 
GDM pregnant.   As tissue explants are not only comprised of just one cell type and 
contain other paracrine mediators, such as immunocytes and vascular cells (non-
trophoblast cells), these may be having an effect on adipsin release.  Furthermore, 
several metabolic and hormonal changes that occur in insulin resistant women could 
contribute to this regulation of placental adipsin expression.  To explore this further, 
future studies are needed. 
 
Adipsin localization has been confirmed in muscle, lungs, adipose tissue and 
peripheral nerves (Chrast et al., 2004, White et al., 1992), also the localization in 
placenta has been reported in mouse placenta (Takeshita et al., 2010).   However, 
there are only few fundamental data regarding the appearance and activity of adipsin 
in placenta.  
Having demonstrated the novel secretion of both adipsin and ASP in the human 
placenta, we then intended to identify the cell types within the placenta that were 
responsible for the synthesis and secretion of these molecules.   It has previously 
been demonstrated in adipose tissue that the non-adipocytes are responsible for the 
release of adipsin (Fain et al., 2007). 
 The placenta is a complex organ, comprised of trophoblast (cytotrophoblast and 
syncytio-trophoblast), endothelial cells, connective tissue, fibroblasts and Hofbauer 
cells. Hofbauer cells are of mesenchymal origin and are present throughout 
pregnancy. These phagocytic cells possess many of the cell surface markers 
associated with macrophages.  Immuno-histochemistry revealed perivascular staining 
of adipsin, in a cell type that was neither endothelial nor trophoblast.  Since positive 
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staining was localized to areas with both fibroblasts and Hofbauer cells, we further 
aimed to identify the responsible cell type using a negative immuno-selection 
technique that  have previously used to isolate cell types from the placenta (Tang et 
al., 2011a).  Use of this technique revealed that both adipsin and ASP were released 
from Hofbauer cells, with negligible release from any of the other cell types such as 
cytotrophoblast and fibroblasts.  Increases in placental macrophage number in obese 
pregnancy have been demonstrated by a several other groups (Challier et al., 2008, 
Farley et al., 2009) and would explain the observed increased release of adipsin and 
ASP from placentae of obese women as well as from placentae of diabetic women.    
The increased release of adipsin and ASP from obese pregnant women, which would 
suggest a higher Hofbauer cell number, might be responsible for this increased 
secretion. 
 Immunoflourescence showed HBC and adipsin co-localization, and culturing 
separated cytotrophoblast, fibroblasts and HBC revealed that both adipsin and ASP 
were released from HBC, with negligible release from any of the other cell types 
seen.  This novel finding indicates that Hofbauer cells release molecules associated 
with regulation of triglyceride metabolism. 
After showing adipsin/ASP might play a role in increasing substrate transfer across 
the placenta, I then focused on mechanisms by which these adipogenic substrates 
might be increased in maternal disease. In terms of the presence of substrates in the 
maternal compartment, I have assessed the role of FGF21. 
FGF21 is predominately a hepatokine, also known to be secreted by adipose tissue.  
Interestingly, human placenta secretes many adipose tissue related proteins and 
hence I sought to investigate whether the human placenta secreted FGF21.  Unlike 
circulating levels, FGF21 secretion into conditioned media was significantly lower 
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in human placental explants from women with GDM compared to lean and obese 
pregnant women. 
Recently, Fibroblast Growth Factor 21 (FGF21) has been described as a regulator of 
metabolism and were positively associated with obesity, metabolic syndrome and in 
type 2 diabetes mellitus (Zhang et al., 2008, Galman et al., 2008, Li et al., 2008, Li et 
al., 2009).   It has been reported that FGF21 alleviated obesity in mice (Coskun et al., 
2008).  Recently, it has also been demonstrated that FGF21 crosses the blood-brain 
barrier (BBB) in mice (Hsuchou et al., 2007).  Another study has examined the 
presence of FGF21 in human CSF and also the CSF concentrations of FGF21 in 
relation to corresponding plasma levels (Tan et al., 2011).  
Given the above, CSF concentrations of FGF21 in relation to corresponding plasma 
levels within these same cohorts of subjects (lean, obese and GDM pregnant) have 
been studied in agreement with recent studies (Zhang et al., 2008, Li et al., 2008, Tan 
et al., 2011).   
I present novel data of CSF and plasma FGF21 levels in women with GDM, obese 
pregnant and matched (age, BMI) controls.  Circulating FGF21 levels were 
significantly higher in women with GDM compared to controls in agreement with 
the only study measuring circulating FGF21 levels in women with GDM (Stein et al., 
2010).  There were no significant differences in plasma FGF21 levels in obese 
pregnant women than the lean pregnant women.  Additionally, there were no 
significant differences in CSF FGF21 levels in women with GDM, obese pregnant 
compared to lean controls. Importantly, the CSF/Plasma FGF21 ratio was 
significantly lower in women with GDM compared to control subjects.  
Furthermore, it is possible that FGF21 has protein binding and these differences in 
binding of protein in lean, obese and GDM pregnant may explain these findings.  
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Moreover, it is possible that the uptake of FGF21 into CSF is reduced in obese 
pregnant women may be secondary to transporters saturation.  However it has been  
reported that FGF21 crosses the blood brain barrier nonsaturably and through slow 
passive diffusion  (Hsuchou et al., 2007), this could explain the above findings.  To 
clarify these points, future studies are needed in future. 
Recently, a landmark study by Sarruf et al. had shown that continuous 
intracerebroventricular infusion of FGF21 stimulated appetite and energy production 
in rats by improving insulin sensitivity via increased insulin induced inhibition of 
hepatic gluconeogenesis (Sarruf et al., 2010). It was proposed that FGF21 engages 
with fibroblast growth factor receptor-1, which is mainly expressed in the arcuate 
and ventromedial nuclei of the hypothalamus (areas of the hypothalamus that also 
mediate the central metabolic effects of insulin, leptin, oleate and glucose) and 
regulates gluconeogenesis (Sarruf et al., 2010).  
In order for FGF21 to impose its central effects, circulating FGF21 should cross the 
blood-brain and/or blood-CSF barriers.  In relation to this, Hsuchou et al. surmised 
that FGF21 traverses the BBB by simple diffusion in mice (Hsuchou et al., 2007).  
My study has found the novel finding of a significantly lower CSF/Plasma FGF21 
ratio in women with GDM compared to obese pregnant as well as lean pregnant 
subjects implies either that there is a deficiency of FGF21 transport across the BBB 
or that discrepancies in the production and/or metabolism of FGF21 by the central 
nervous system may explain the differences in CSF/plasma FGF21 ratio between the 
GDM and obese pregnant as well as lean controls in this study. 
In relation to this, Yamashita et al. had reported that FGF23 is produced in the brain, 
particularly, by the ventrolateral thalamic nuclei (Yamashita et al., 2000). It is thus 
possible that FGF21 may also be produced in the brain (Tan et al., 2011).  Moreover, 
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it is probable that FGF21 has protein binding, and that differences in protein binding 
between GDM and obese pregnant as well as lean pregnant subjects may also explain 
these findings.  Furthermore, it is potential that the efficiency of FGF21 uptake into 
the CSF is decreased in GDM subjects possibly secondary to saturation of 
transporters.  When saying this, the evidence by Hsuchou et al. who had shown that 
FGF21 crosses the BBB non-saturably (Hsuchou et al., 2007) has been considered.  
The coexistence of non-saturable and saturable mechanisms is plausible given that 
other adipokines, for example, leptin, have been shown to cross the BBB through 
both non-saturable and saturable mechanisms (Nam et al., 2001).  
Taken together, given that FGF21 crosses the BBB via a relatively slow passive 
diffusion and exhibits considerable degradation in the central nervous system 
(Hsuchou et al., 2007) as well as my findings of lower secretion of FGF21 by GDM 
placenta; aberrations in the production of FGF21 within the brain may be the main 
explanation of the lower CSF/FGF21 ratio observed in GDM subjects than the other 
two study subjects (obese pregnant and lean pregnant).  
Given the recently reported central nervous system actions of FGF21 (Sarruf et al., 
2010), it could be hypothesized that the relatively lower levels of FGF21 in CSF in 
GDM subjects may lead to dysfunctional FGF21 signaling in the brain and in turn 
contribute to the insulin resistance of GDM subjects in line with the report of Sarruf 
et al. This is plausible as dysfunctional central nervous system signaling of other 
growth factors and adipokines such as insulin and leptin, has been reported (Morton 
et al., 2006).  Further studies are needed to clarify these points. 
In addition, this study has reported for the first time the secretion of FGF21 by the 
placenta.  It has been also found that the secretion of FGF21 from human placental 
explants of women with GDM was significantly lower compared to obese pregnant 
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as well as lean pregnant women.  This might postulate an impact upon both maternal 
and fetal physiology and lead to the complications observed in women with GDM. 
Strengths of this study include, the relatively large number of subjects investigated, 
the identification of placental HBC as the source of adipsin and ASP, and support of 
this findings from results in ex vivo explants.   
Limitations include, the use of estimates of insulin sensitivity rather than measuring 
this parameter using euglycemic hyperinsulinemic clamps (which understandably 
would not receive ethical approval in our institution), and the lack of information 
about body fat distribution in the pregnant participants (although leptin was utilized 
as a surrogate marker of fat mass).   Furthermore, since only Caucasian women were 
investigated, these results may not apply in members of other ethnicities.  Finally, 
whether high adipsin levels in the fetus may be casually involved in driving up the 
birth weight and insulin resistance, or just reflect a phenomenon of higher 
permeability or diffusion for adipsin and ASP at the fetal end of the cord needs to be 
investigated in future studies. 
 Furthermore, limitation of the FGF21 study is that the presence of other members of 
the FGF family in human CSF has not been assessed. Moreover, the energy status in 
these study subjects has not been measured. Given that intracerebroventricular 
infusion of FGF21 increased appetite and energy production in rats (Sarruf et al., 
2010), it would be of interest to establish the relationship between the levels of other 
members of the FGF family in human CSF with FGF21 and could have been 
correlated with the energy status of these study subjects. Finally, the role of FGF21 
derived from the placenta on both mother and child has not been explored.  
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Conclusions 
In conclusion, given the relative insulin resistance in pregnancy (particularly in obese 
pregnancy and GDM pregnancy), these molecules may play a role in triglyceride 
metabolism in the fetus.  Having demonstrated the concentrations of adipsin were 
considerably higher in the cord blood than in the mothers and this was exacerbated in 
obese pregnancies than GDM pregnancies.   It seems that adipsin has an influential 
effect in placental formation and for the development of growing embryo through the 
other effects such as lipid metabolism in placenta.  Additionally, having identified 
the source of adipsin and ASP as coming from the Hofbauer cells (specialized 
placental macrophages) equally, these data place HBC as the source of these 
metabolically active molecules and implicates these cells in nutrient sensing at the 
materno-fetal interface. The central actions of FGF21 in GDM subjects may be 
pivotal in the pathogenesis of insulin resistance in GDM subjects.  The significance 
of FGF21 produced by the placenta remains by and large unexplored. Future research 
should aim to reveal these points. 
This study has aimed to improve the understanding the effects of obesity in 
pregnancy as well as diabetic pregnancy on changes in physiological and metabolic 
factors that might influence intrauterine environment for fetus and pregnancy 
outcomes in particular fetal macrosomia, since it predisposes to obesity and Type 2 
diabetes mellitus later in life. 
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